Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
44.0 /100
Rank 52 out of 131 Industries -
Advance/Decline
137/254
-
No. of Companies391
-
Avg. Market Cap9,882
-
Price to Earning Ratio4.34
-
Price to Earning Growth Ratio1.44
-
Price to Book Ratio42.95
-
Return on Equity49.96
-
Return on Capital Employed-
-
Return on Assets12.11
-
Dividend yield 1 year %0.87 %
-
Net Profit Growth Annual YoY %-29.83 %
-
Net Profit Growth Qtr YoY %-46.26 %
-
Net Profit Growth Qtr QoQ %-43.48 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie Inc |
|
377,291.6
|
213.7
|
L
 -0.4%
H
212.3
215.2
|
L
 -1.4%
H
208.3
216.7
|
L
 10.8%
H
190.7
218.7
|
L
 21.7%
H
168.1
218.7
|
L
 20.2%
H
153.6
218.7
|
L
 34.8%
H
131.0
218.7
|
L
 192.7%
H
62.6
218.7
|
L
 257.8%
H
45.5
218.7
|
Adc Therapeutics SA |
|
164.4
|
1.7
|
L
 -5.0%
H
1.7
1.8
|
L
 -1.7%
H
1.6
1.9
|
L
 6.3%
H
1.5
1.9
|
L
 -20.2%
H
1.4
2.2
|
L
 -55.0%
H
1.4
5.4
|
L
 -88.4%
H
0.4
16.0
|
L
H
0.4
56.6
|
L
H
0.4
56.6
|
Amneal Pharmaceuticals Inc... |
|
2,681.2
|
8.7
|
L
 0.4%
H
8.3
8.7
|
L
 -0.6%
H
8.3
9.1
|
L
 11.9%
H
7.6
9.2
|
L
 7.2%
H
7.6
9.2
|
L
 57.3%
H
5.2
9.5
|
L
 108.4%
H
1.2
9.5
|
L
 190.3%
H
1.2
9.5
|
L
 -81.3%
H
1.2
52.1
|
Annovis Bio Inc |
|
34.9
|
1.8
|
L
 -7.3%
H
1.8
1.9
|
L
 11.9%
H
1.5
2.0
|
L
 -34.4%
H
1.5
2.8
|
L
 -65.0%
H
1.5
5.6
|
L
 -80.3%
H
1.5
20
|
L
 -87.2%
H
1.5
23.9
|
L
 -44.1%
H
1.5
132
|
L
H
1.5
132
|
Bausch Health Companies Inc |
|
2,586.6
|
7.0
|
L
 -0.1%
H
7
7.2
|
L
 0.4%
H
6.7
7.2
|
L
 14.1%
H
6.1
7.9
|
L
 -8.5%
H
6.1
8.3
|
L
 -23.6%
H
4.0
11.5
|
L
 -70.0%
H
4.0
24.3
|
L
 -52.2%
H
4.0
34.8
|
L
 -96.5%
H
4.0
263.8
|
Bristol-Myers Squibb Co. |
|
121,697.8
|
60.0
|
L
 0.0%
H
59.5
60.3
|
L
 -5.0%
H
58.4
63.3
|
L
 11.3%
H
53.5
63.3
|
L
 4.0%
H
53.5
63.3
|
L
 14.6%
H
39.4
63.3
|
L
 -15.0%
H
39.4
81.4
|
L
 10.9%
H
39.4
81.4
|
L
 -11.3%
H
39.4
81.4
|
Emergent Biosolutions Inc |
|
310.3
|
5.7
|
L
 -1.4%
H
5.6
5.8
|
L
 1.6%
H
5.3
6.4
|
L
 -41.3%
H
5.0
10.0
|
L
 -33.8%
H
5.0
12.0
|
L
 133.1%
H
1.8
15.1
|
L
 -85.6%
H
1.4
45.1
|
L
 -90.1%
H
1.4
137.6
|
L
 -79.5%
H
1.4
137.6
|
GSK Plc - ADR |
|
81,976.8
|
40.3
|
L
 0.1%
H
40.1
40.3
|
L
 -0.1%
H
38.8
40.5
|
L
 11.3%
H
36.1
40.8
|
L
 17.7%
H
31.7
40.8
|
L
 -4.6%
H
31.7
45.9
|
L
 -8.1%
H
28.5
47.8
|
L
 7.4%
H
28.5
47.8
|
L
 -16.2%
H
28.5
50.0
|
Johnson & Johnson |
|
395,672.9
|
164.2
|
L
 0.8%
H
163.0
164.9
|
L
 -2.1%
H
161.1
167.3
|
L
 5.2%
H
153.2
170.0
|
L
 12.1%
H
140.7
170.0
|
L
 3.8%
H
140.7
170.0
|
L
 -7.1%
H
140.7
186.7
|
L
 20.2%
H
109.2
186.7
|
L
 64.4%
H
81.8
186.7
|
Lilly(Eli) & Co |
|
736,229.9
|
819.7
|
L
 -0.6%
H
812.6
836.3
|
L
 -1.2%
H
795.4
836.3
|
L
 -2.9%
H
795.4
935.6
|
L
 5.5%
H
725.0
935.6
|
L
 8.7%
H
711.4
972.5
|
L
 187.1%
H
276.8
972.5
|
L
 472.4%
H
117.1
972.5
|
L
 1057.1%
H
64.2
972.5
|
Merck & Co Inc |
|
239,341.9
|
94.8
|
L
 0.0%
H
93.8
95.4
|
L
 -0.5%
H
92.9
96.3
|
L
 14.1%
H
81.0
97.4
|
L
 -5.3%
H
81.0
103.0
|
L
 -22.0%
H
81.0
134.6
|
L
 20.0%
H
78.6
134.6
|
L
 33.3%
H
62.3
134.6
|
L
 75.9%
H
43.6
134.6
|
Novo Nordisk - ADR |
|
359,696.5
|
81.0
|
L
 1.1%
H
80.2
82.6
|
L
 2.6%
H
73.8
82.6
|
L
 4.1%
H
73.8
93.8
|
L
 -25.0%
H
73.8
109.0
|
L
 -38.8%
H
73.8
148.2
|
L
 47.5%
H
47.5
148.2
|
L
 193.7%
H
24.6
148.2
|
L
 235.8%
H
15.5
148.2
|
Novartis AG - ADR |
|
222,158.0
|
112.5
|
L
 0.2%
H
111.4
112.5
|
L
 -2.6%
H
107.6
113.8
|
L
 6.7%
H
106.1
116.9
|
L
 13.5%
H
96.1
116.9
|
L
 15.6%
H
92.4
120.9
|
L
 30.1%
H
74.1
120.9
|
L
 46.2%
H
70.2
120.9
|
L
 30.4%
H
59.2
120.9
|
Organon & Co. |
|
4,044.7
|
15.7
|
L
 0.4%
H
15.3
15.7
|
L
 -0.3%
H
14.8
15.8
|
L
 2.6%
H
14.1
16.2
|
L
 6.2%
H
13.9
17.2
|
L
 -14.2%
H
13.9
23.1
|
L
 -54.3%
H
10.8
39.1
|
L
H
10.8
39.5
|
L
H
10.8
39.5
|
Prestige Consumer Healthca... |
|
4,171.1
|
84.2
|
L
 -0.8%
H
83.6
84.8
|
L
 -3.1%
H
81.8
87.5
|
L
 -2.1%
H
81.8
90.0
|
L
 4.7%
H
72.7
90.0
|
L
 12.8%
H
62.4
90.0
|
L
 50.6%
H
48.5
90.0
|
L
 185.2%
H
28.0
90.0
|
L
 104.8%
H
26.3
90.0
|
Pfizer Inc. |
|
149,386.1
|
26.3
|
L
 1.2%
H
26.1
26.3
|
L
 -1.1%
H
25.5
26.6
|
L
 3.2%
H
25.4
27.2
|
L
 0.3%
H
25.2
27.6
|
L
 -5.7%
H
24.5
31.5
|
L
 -51.4%
H
24.5
56.3
|
L
 -13.5%
H
24.5
61.7
|
L
 -18.6%
H
24.5
61.7
|
Perrigo Company plc |
|
3,812.7
|
27.9
|
L
 -1.2%
H
27.9
29.1
|
L
 1.8%
H
26.6
29.1
|
L
 14.1%
H
23.9
30.9
|
L
 4.9%
H
23.1
30.9
|
L
 -8%
H
23.1
33.5
|
L
 -27.5%
H
23.1
43.9
|
L
 -43.7%
H
23.1
58.8
|
L
 -83.8%
H
23.1
215.7
|
Dr. Reddy`s Laboratories L... |
|
11,114.3
|
13.3
|
L
 0.9%
H
13.3
13.4
|
L
 5.0%
H
12.5
13.4
|
L
 -1.9%
H
12.5
13.7
|
L
 -7.9%
H
12.5
16.0
|
L
 -11.4%
H
12.5
74.9
|
L
 24.8%
H
9.9
74.9
|
L
 79.8%
H
6.7
74.9
|
L
 20.6%
H
5.6
74.9
|
Takeda Pharmaceutical Co -... |
|
47,899.5
|
15.2
|
L
 -0.1%
H
15.0
15.2
|
L
 0.8%
H
14.8
15.2
|
L
 12.0%
H
13.7
15.2
|
L
 13.5%
H
12.8
15.2
|
L
 4.8%
H
12.6
15.2
|
L
 1.0%
H
12.3
17.2
|
L
 8.2%
H
12.3
20
|
L
 -42.3%
H
12.3
30.6
|
Teva- Pharmaceutical Indus... |
|
18,723.0
|
16.3
|
L
 -2.2%
H
16.2
16.7
|
L
 11.4%
H
14.7
16.9
|
L
 0.6%
H
14.4
17.6
|
L
 -21.7%
H
14.4
22.8
|
L
 21.7%
H
12.5
22.8
|
L
 107.4%
H
6.8
22.8
|
L
 122.6%
H
6.3
22.8
|
L
 -73.4%
H
6.1
72.3
|
Zoetis Inc - Ordinary Shar... |
|
73,442.4
|
164.0
|
L
 -0.7%
H
163.2
165.4
|
L
 -4.5%
H
158.3
171.8
|
L
 4.1%
H
154.3
177
|
L
 -4.0%
H
154.3
177.4
|
L
 -5.0%
H
144.8
200.2
|
L
 -15.3%
H
124.2
201.9
|
L
 47.7%
H
90.1
249.3
|
L
 247.8%
H
37.7
249.3
|
Biohaven Ltd |
|
2,941.2
|
28.8
|
L
 -2.8%
H
28.7
29.6
|
L
 4.3%
H
27.0
30.4
|
L
 -30.4%
H
27.0
42.3
|
L
 -27.0%
H
27.0
44.3
|
L
 -49.5%
H
26.8
60.5
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
Abeona Therapeutics Inc |
|
225.8
|
5.2
|
L
 -2.3%
H
5.1
5.3
|
L
 2.8%
H
5.0
5.6
|
L
 -14.0%
H
4.9
6.1
|
L
 -11.9%
H
4.9
6.2
|
L
 -40.0%
H
3.1
8.5
|
L
 -31.4%
H
2.2
9.4
|
L
 -89.8%
H
2.2
94.8
|
L
 -93.7%
H
2.2
568.8
|
Oruka Therapeutics Inc. |
|
432.1
|
11.5
|
L
 -2.9%
H
11.4
11.9
|
L
 5.5%
H
10.2
12.3
|
L
 3.2%
H
9.4
12.3
|
L
 -48.6%
H
9.4
23.5
|
L
 -43.1%
H
2.2
53.9
|
L
 -59.1%
H
2.2
53.9
|
L
 -61.5%
H
2.2
264
|
L
 -99.0%
H
2.2
2343.6
|
Acumen Pharmaceuticals Inc |
|
75.7
|
1.3
|
L
 -1.6%
H
1.2
1.4
|
L
 5%
H
1.2
1.4
|
L
 -13.1%
H
1.1
1.5
|
L
 -35.7%
H
1.1
2.0
|
L
 -69.9%
H
1.1
4.4
|
L
 -79.7%
H
1.1
11.3
|
L
H
1.1
27.0
|
L
H
1.1
27.0
|
Arbutus Biopharma Corp |
|
604.5
|
3.2
|
L
 -2.7%
H
3.2
3.3
|
L
 2.6%
H
3.0
3.5
|
L
 -3.0%
H
3.0
3.7
|
L
 -7.8%
H
3.0
3.7
|
L
 21.8%
H
2.3
4.7
|
L
 5.6%
H
1.7
4.7
|
L
 151.2%
H
0.9
9.0
|
L
 -84.1%
H
0.8
21.4
|
ABVC BioPharma Inc |
|
15.4
|
0.7
|
L
H
0.7
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 41.3%
H
0.5
0.9
|
L
 35.4%
H
0.4
0.9
|
L
 -44.4%
H
0.4
1.7
|
L
 -97.1%
H
0.4
31.3
|
L
 -97.7%
H
0.4
299.5
|
L
 -100.0%
H
0.4
2865.3
|
Acadia Pharmaceuticals Inc |
|
2,868.8
|
17.2
|
L
H
16.8
17.3
|
L
 0.1%
H
16.6
17.7
|
L
 -14.2%
H
16.6
20.7
|
L
 -1.6%
H
16.3
20.7
|
L
 -6.9%
H
14.2
20.7
|
L
 -27.9%
H
12.2
33.9
|
L
 -50.0%
H
12.2
58.7
|
L
 -49.9%
H
12.2
58.7
|
Adicet Bio Inc |
|
65.3
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 4.0%
H
0.7
0.8
|
L
 -20.2%
H
0.7
1.0
|
L
 -17.7%
H
0.7
1.1
|
L
 -60.5%
H
0.7
2.4
|
L
 -95.1%
H
0.7
21.9
|
L
 -88.4%
H
0.7
21.9
|
L
H
0.7
147.7
|
Achieve Life Sciences Inc. |
|
96.8
|
2.8
|
L
 -4.1%
H
2.8
3.0
|
L
 -8.8%
H
2.5
3.0
|
L
 -18.4%
H
2.5
3.5
|
L
 -32.9%
H
2.5
4.2
|
L
 -39.2%
H
2.5
5.6
|
L
 -59.6%
H
2
10.3
|
L
 -48.4%
H
2
18.3
|
L
 -99.9%
H
2
9020
|
AC Immune SA |
|
220.9
|
2.2
|
L
 -0.5%
H
2.2
2.3
|
L
 -8.3%
H
2.2
2.4
|
L
 -19.7%
H
2.2
2.7
|
L
 -25.2%
H
2.2
3.1
|
L
 -37.1%
H
2.2
5.0
|
L
 -41.8%
H
1.7
5.1
|
L
 -53.6%
H
1.7
13
|
L
H
1.7
20.0
|
Aclaris Therapeutics Inc |
|
168.7
|
1.6
|
L
 -1.3%
H
1.6
1.6
|
L
 -6.0%
H
1.5
1.7
|
L
 -33.1%
H
1.5
2.4
|
L
 -52.2%
H
1.5
3.3
|
L
 33.3%
H
1.0
5.2
|
L
 -90.2%
H
0.6
19.0
|
L
 69.6%
H
0.6
30.4
|
L
H
0.6
33.9
|
Acrivon Therapeutics Inc |
|
168.1
|
5.4
|
L
 -1.8%
H
5.3
5.4
|
L
 2.1%
H
5.1
5.6
|
L
 -0.4%
H
5
6.1
|
L
 -24.4%
H
4.7
8
|
L
 -12.8%
H
4.7
11.9
|
L
H
3.2
25.5
|
L
H
3.2
25.5
|
L
H
3.2
25.5
|
Acelrx Pharmaceuticals Inc |
|
10.0
|
0.6
|
L
 -47.8%
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
 -91.8%
H
0.4
7.7
|
L
 -96.9%
H
0.4
58.8
|
L
 -99.3%
H
0.4
117.6
|
Grace Therapeutics Inc. |
|
32.5
|
2.4
|
L
 3.5%
H
2.4
2.5
|
L
 -1.3%
H
2.1
2.5
|
L
 -31.3%
H
2.1
3.5
|
L
 -38.9%
H
2.1
4.7
|
L
 -29.9%
H
2.1
5.0
|
L
 -63.1%
H
1.7
8.1
|
L
 -82.0%
H
1.7
58.6
|
L
 -99.0%
H
1.7
249.6
|
Acurx Pharmaceuticals Inc |
|
9.6
|
0.4
|
L
 -6.4%
H
0.4
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
 -40.5%
H
0.4
0.9
|
L
 -48.8%
H
0.4
1.3
|
L
 -83.8%
H
0.4
3.3
|
L
 -88.3%
H
0.4
8.8
|
L
H
0.4
8.8
|
L
H
0.4
8.8
|
Adial Pharmaceuticals Inc |
|
4.9
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 2.8%
H
0.6
0.8
|
L
H
0.6
1.3
|
L
 -34.5%
H
0.6
1.3
|
L
 -53.2%
H
0.6
3.1
|
L
 -98.5%
H
0.6
56.6
|
L
 -97.7%
H
0.6
127
|
L
H
0.6
236
|
Adverum Biotechnologies Inc |
|
94.0
|
4.5
|
L
 -4.4%
H
4.4
4.7
|
L
 2.7%
H
4.2
4.9
|
L
 1.4%
H
3.5
5.1
|
L
 -13.6%
H
3.5
5.3
|
L
 -97.3%
H
3.5
180
|
L
 -96.7%
H
3.5
297
|
L
 -99.5%
H
3.5
2698
|
L
 -99.9%
H
3.5
4518.3
|
Aeterna Zentaris Inc. |
|
10.9
|
3.5
|
L
 9.8%
H
3.2
3.5
|
L
 29.7%
H
2.0
3.7
|
L
 26.5%
H
2.0
3.7
|
L
 20.8%
H
2.0
3.7
|
L
 60.8%
H
2.0
11.1
|
L
 -60.1%
H
1.4
11.1
|
L
 -71.5%
H
1.4
90.5
|
L
 -99.7%
H
1.4
1700
|
Agios Pharmaceuticals Inc |
|
1,802.5
|
31.5
|
L
 -1.7%
H
30.8
31.9
|
L
 -1.7%
H
30.6
33.1
|
L
 -5.3%
H
30.6
36.2
|
L
 -25.0%
H
30.6
42.4
|
L
 5.1%
H
27.1
62.6
|
L
 7.2%
H
16.8
62.6
|
L
 -2.8%
H
16.8
62.6
|
L
 -70.8%
H
16.8
126.4
|
Akebia Therapeutics Inc. |
|
595.3
|
2.5
|
L
 5%
H
2.3
2.5
|
L
 35.5%
H
1.5
2.5
|
L
 18.3%
H
1.5
2.5
|
L
 36.2%
H
1.5
2.5
|
L
 48.2%
H
0.8
2.5
|
L
 1.6%
H
0.2
2.6
|
L
 -50.4%
H
0.2
13.7
|
L
 -80.3%
H
0.2
20.3
|
Akero Therapeutics Inc |
|
3,442.0
|
43.2
|
L
 -3.6%
H
43.1
44.4
|
L
 3.7%
H
41.6
47.1
|
L
 -14.4%
H
41.2
52.7
|
L
 41.2%
H
21.3
58.4
|
L
 57.0%
H
17.9
58.4
|
L
 198.1%
H
7.5
58.4
|
L
 187.6%
H
7.5
58.4
|
L
H
7.5
58.4
|
Aligos Therapeutics Inc |
|
66.3
|
10.8
|
L
 -7.1%
H
10.7
11.4
|
L
 4.1%
H
9.7
12.1
|
L
 -54.2%
H
9.5
24.3
|
L
 -64.1%
H
9.5
46.3
|
L
 -53.0%
H
6.8
46.3
|
L
 -84.2%
H
6.8
74.8
|
L
H
6.8
937.8
|
L
H
6.8
937.8
|
Alkermes plc |
|
5,582.5
|
34.3
|
L
 -0.1%
H
33.7
34.7
|
L
 -2.6%
H
33.0
35.6
|
L
 -4.4%
H
33.0
36.5
|
L
 11.6%
H
27.7
36.5
|
L
 19.4%
H
22.9
36.5
|
L
 32.6%
H
21.8
36.5
|
L
 157.5%
H
12.0
36.5
|
L
 -48.4%
H
12.0
80.7
|
Allakos Inc |
|
22.6
|
0.3
|
L
H
0.3
0.3
|
L
H
0.2
0.3
|
L
 -19.4%
H
0.2
0.3
|
L
 -76.9%
H
0.2
1.4
|
L
 -80.9%
H
0.2
1.6
|
L
 -95.9%
H
0.2
8.7
|
L
 -99.5%
H
0.2
158.0
|
L
H
0.2
158.0
|
Allarity Therapeutics Inc |
|
3.8
|
0.9
|
L
 -8.6%
H
0.8
1.0
|
L
 -24.1%
H
0.8
1.1
|
L
 -13.3%
H
0.7
1.2
|
L
 -22.7%
H
0.7
2.0
|
L
 -87.8%
H
0.1
116
|
L
 -100.0%
H
0.1
94640
|
L
H
0.1
509600
|
L
H
0.1
509600
|
Alnylam Pharmaceuticals Inc |
|
32,061.4
|
247.7
|
L
 -2.2%
H
246.9
263.3
|
L
 6.3%
H
230.9
263.3
|
L
 -3.4%
H
230.9
263.3
|
L
 2.0%
H
230.9
287.2
|
L
 65.9%
H
142.0
304.4
|
L
 51.9%
H
117.6
304.4
|
L
 140.4%
H
92.6
304.4
|
L
 113.0%
H
31.4
304.4
|
Rein Therapeutics Inc. |
|
41.2
|
1.9
|
L
 -6.4%
H
1.9
2.0
|
L
 -4.0%
H
1.8
2.1
|
L
 -22.1%
H
1.7
3.0
|
L
 -1.0%
H
1.7
3.5
|
L
 -66.0%
H
1.6
7.4
|
L
 -77.9%
H
1.0
15
|
L
 -71.2%
H
1.0
49.4
|
L
H
1.0
309.6
|
Alzamend Neuro Inc |
|
6.4
|
1.0
|
L
 7.8%
H
0.8
1
|
L
 36.6%
H
0.6
1
|
L
 -11.0%
H
0.6
1.2
|
L
 -24.8%
H
0.6
1.3
|
L
 4.3%
H
0.4
15.1
|
L
 -93.7%
H
0.4
22.5
|
L
H
0.4
503.3
|
L
H
0.4
503.3
|
Amylyx Pharmaceuticals Inc |
|
325.2
|
3.7
|
L
 -2.1%
H
3.6
3.8
|
L
 5.2%
H
3.3
4.1
|
L
 -1.3%
H
2.6
4.1
|
L
 -14.3%
H
2.6
4.3
|
L
 13.3%
H
1.6
7.3
|
L
 -84.0%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
Amphastar Pharmaceuticals Inc |
|
1,301.8
|
27.3
|
L
 -1.3%
H
27.2
27.8
|
L
 -3.8%
H
25.9
28.4
|
L
 -11.9%
H
25.9
32.7
|
L
 -33.1%
H
25.9
41.1
|
L
 -36.5%
H
25.9
54.0
|
L
 -20.1%
H
25.9
67.7
|
L
 88.4%
H
12.3
67.7
|
L
 80.3%
H
10.5
67.7
|
Anebulo Pharmaceuticals Inc |
|
69.0
|
1.7
|
L
 7.7%
H
1.5
1.7
|
L
 50%
H
1.1
1.8
|
L
 26.3%
H
0.9
1.8
|
L
 28.2%
H
0.8
1.9
|
L
 -33.9%
H
0.8
3.3
|
L
 -75.1%
H
0.8
7.7
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
Annexon Inc |
|
276.5
|
2.5
|
L
 -8.4%
H
2.5
2.8
|
L
 -3.5%
H
2.4
3.5
|
L
 -17.9%
H
2.3
3.5
|
L
 -49.5%
H
2.3
5.7
|
L
 -62.3%
H
2.3
8.4
|
L
 -35.4%
H
1.6
8.4
|
L
H
1.6
38.0
|
L
H
1.6
38.0
|
Apollomics Inc - Ordinary ... |
|
8.8
|
8.0
|
L
 -0.1%
H
7.5
8.0
|
L
 5.4%
H
7
8.7
|
L
 12.0%
H
6.2
8.7
|
L
 6.1%
H
6.2
12
|
L
 -86.8%
H
0.1
75
|
L
 -99.2%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
Apellis Pharmaceuticals Inc |
|
3,095.2
|
24.7
|
L
 -1.8%
H
24.1
25.0
|
L
 -1.9%
H
24.1
25.9
|
L
 -10%
H
23.8
29.0
|
L
 -28.6%
H
23.8
35.7
|
L
 -56.5%
H
23.8
59.9
|
L
 -47.4%
H
19.8
94.8
|
L
 37.7%
H
16.9
94.8
|
L
H
11.5
94.8
|
Applied Therapeutics Inc |
|
59.3
|
0.5
|
L
 -7.3%
H
0.5
0.6
|
L
H
0.5
0.6
|
L
 -21.5%
H
0.4
0.7
|
L
 -53.6%
H
0.4
1.1
|
L
 -91.5%
H
0.4
10.6
|
L
 -72.6%
H
0.4
10.6
|
L
 -97.8%
H
0.4
52.0
|
L
H
0.4
57.4
|
Aptorum Group Ltd - Ordina... |
|
6.9
|
1.0
|
L
 2.1%
H
0.9
1.0
|
L
 6.7%
H
0.9
1
|
L
 -19.3%
H
0.8
1.2
|
L
 24.7%
H
0.7
7.5
|
L
 -86.5%
H
0.5
12.0
|
L
 -92.9%
H
0.5
17.8
|
L
 -95.3%
H
0.5
142.3
|
L
H
0.5
332.8
|
Aprea Therapeutics Inc |
|
12.8
|
2.4
|
L
 0.4%
H
2.3
2.4
|
L
 5.4%
H
2.3
2.8
|
L
 -34.5%
H
2.2
3.7
|
L
 -29.6%
H
2.2
5
|
L
 -62.0%
H
2.2
6.9
|
L
 -93.5%
H
2.2
40.8
|
L
 -99.7%
H
2.2
822.3
|
L
H
2.2
1062.2
|
Aptose Biosciences Inc |
|
8.0
|
3.7
|
L
 -1.3%
H
3.6
4.0
|
L
 11.6%
H
3.1
4.0
|
L
 -30.7%
H
0.1
7.7
|
L
 -33.6%
H
0.1
11.7
|
L
 -91.8%
H
0.1
51.6
|
L
 -99.3%
H
0.1
697.5
|
L
 -99.8%
H
0.1
4050
|
L
 -99.9%
H
0.1
4163.6
|
Aquestive Therapeutics Inc |
|
269.9
|
2.7
|
L
 -4.6%
H
2.7
2.9
|
L
 7.5%
H
2.5
3.1
|
L
 -17.8%
H
2.5
3.4
|
L
 -29.1%
H
2.5
3.9
|
L
 -55.2%
H
2.2
6.2
|
L
 -5.2%
H
0.6
6.2
|
L
 53.4%
H
0.6
9.5
|
L
H
0.6
20.7
|
Arcturus Therapeutics Hold... |
|
371.8
|
13.7
|
L
 -3.2%
H
13.4
14.4
|
L
 -4.1%
H
12.8
14.8
|
L
 -24.0%
H
12.8
19.3
|
L
 -12.8%
H
12.8
21.3
|
L
 -62.2%
H
12.8
45
|
L
 -42.5%
H
11.7
45
|
L
 -2.0%
H
11.2
129.7
|
L
 -62.9%
H
4.1
129.7
|
Ardelyx Inc |
|
1,270.4
|
5.3
|
L
 -1.7%
H
5.2
5.4
|
L
 1.7%
H
5.2
5.7
|
L
 -7.9%
H
4.8
6.6
|
L
 0.6%
H
4.4
6.6
|
L
 -34.2%
H
4.3
9.3
|
L
 412.5%
H
0.5
10.1
|
L
 8.3%
H
0.5
10.1
|
L
 -65.9%
H
0.5
22.5
|
Arcutis Biotherapeutics Inc |
|
1,899.4
|
16.0
|
L
 -2.5%
H
15.5
16.4
|
L
 11.3%
H
14.2
17.7
|
L
 25.3%
H
11.8
17.7
|
L
 13.2%
H
11.1
17.7
|
L
 50.2%
H
7.0
17.7
|
L
 -6.5%
H
1.8
27.4
|
L
 -16.3%
H
1.8
40.9
|
L
H
1.8
40.9
|
Artelo Biosciences Inc |
|
3.1
|
1.0
|
L
H
1.0
1.0
|
L
 -4.0%
H
0.9
1.0
|
L
 -20.2%
H
0.9
1.3
|
L
 -6.9%
H
0.9
1.6
|
L
 -34.0%
H
0.9
1.7
|
L
 -84.4%
H
0.9
11.1
|
L
 -90.4%
H
0.9
55.1
|
L
H
0.9
324
|
Assembly Biosciences Inc |
|
68.0
|
10.7
|
L
 1.0%
H
10.3
10.8
|
L
 -4.0%
H
10.3
11.4
|
L
 -17.8%
H
10.3
13.8
|
L
 -25.1%
H
10.3
18.1
|
L
 -12.1%
H
10.3
19.9
|
L
 -47.9%
H
7.7
29.0
|
L
 -92.7%
H
7.7
334.1
|
L
 -93.5%
H
7.7
808.3
|
ASP Isotopes Inc |
|
300.6
|
4.2
|
L
 -1.4%
H
4.1
4.3
|
L
 7.1%
H
3.9
4.3
|
L
 -20.4%
H
3.7
5.4
|
L
 -22.6%
H
3.7
7
|
L
 4.5%
H
1.9
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Assertio Holdings Inc |
|
69.9
|
0.7
|
L
H
0.7
0.7
|
L
 -4.0%
H
0.7
0.8
|
L
 -13.1%
H
0.7
0.9
|
L
 -20.7%
H
0.7
0.9
|
L
 -34.8%
H
0.7
1.8
|
L
 -73.2%
H
0.7
8.0
|
L
 -75.5%
H
0.7
8.0
|
L
 -99.3%
H
0.7
135.0
|
ATAI Life Sciences N.V. |
|
263.8
|
1.4
|
L
 -6.9%
H
1.4
1.4
|
L
 -3.6%
H
1.3
1.5
|
L
 -40.9%
H
1.3
2.4
|
L
 3.0%
H
1.2
2.6
|
L
 -23.2%
H
1.0
2.9
|
L
 -75.4%
H
1.0
5.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
180 Life Sciences Corp |
|
3.3
|
1.1
|
L
 -1.9%
H
1.0
1.1
|
L
 -7.1%
H
1.0
1.2
|
L
 -21.1%
H
1.0
1.4
|
L
 -40.7%
H
1.0
2.8
|
L
 -70%
H
1.0
17.8
|
L
 -99.9%
H
1.0
1170.4
|
L
 -100.0%
H
1.0
4957.1
|
L
H
1.0
4957.1
|
Atossa Therapeutics Inc |
|
90.6
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 -2.7%
H
0.7
0.8
|
L
 -13.3%
H
0.7
0.9
|
L
 -30.8%
H
0.7
1.1
|
L
 -44.2%
H
0.7
2.3
|
L
 -48.2%
H
0.5
2.3
|
L
 -13.3%
H
0.5
9.8
|
L
 -99.8%
H
0.5
392.4
|
Atara Biotherapeutics Inc |
|
39.9
|
6.8
|
L
 -5.0%
H
6.8
7.2
|
L
 10.6%
H
5.9
7.6
|
L
 -20.7%
H
5.9
9.1
|
L
 -34.2%
H
5.4
18.7
|
L
 -56.1%
H
0.4
20.8
|
L
 -97.1%
H
0.4
250.3
|
L
 -95.2%
H
0.4
705
|
L
 -99.2%
H
0.4
1639
|
Avenue Therapeutics Inc |
|
0.9
|
0.4
|
L
 -50.6%
H
0.4
0.6
|
L
 -59.2%
H
0.4
1.1
|
L
 -69.1%
H
0.4
1.4
|
L
 -74.7%
H
0.4
2.2
|
L
 -100.0%
H
0.4
956.3
|
L
 -100.0%
H
0.4
93656.3
|
L
 -100.0%
H
0.4
1041170.6
|
L
H
0.4
1041170.6
|
Astria Therapeutics Inc |
|
365.7
|
6.5
|
L
H
6.2
6.6
|
L
 11.3%
H
5.7
7.3
|
L
 -8.2%
H
5.7
7.3
|
L
 -33.5%
H
5.7
9.8
|
L
 -58.1%
H
5.7
16.9
|
L
 -8.6%
H
2.4
16.9
|
L
 -67.1%
H
2.4
51.5
|
L
H
2.4
1017.6
|
Atea Pharmaceuticals Inc |
|
269.4
|
3.2
|
L
 0.6%
H
3.0
3.2
|
L
 7.9%
H
2.8
3.2
|
L
H
2.8
3.2
|
L
 1.9%
H
2.8
3.6
|
L
 -21.5%
H
2.8
4.1
|
L
 -52.2%
H
2.8
9.8
|
L
H
2.8
94.2
|
L
H
2.8
94.2
|
Avalo Therapeutics Inc |
|
78.8
|
7.5
|
L
 -2.5%
H
7.4
7.7
|
L
 4.3%
H
7.1
8.4
|
L
 2.0%
H
6.4
11.2
|
L
 -19.1%
H
6.0
11.2
|
L
 71.6%
H
4.4
34.5
|
L
 -16.9%
H
0.0
34.5
|
L
 -69.5%
H
0.0
54
|
L
H
0.0
91.8
|
Aytu BioPharma Inc |
|
7.4
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -4.8%
H
1.2
1.3
|
L
 -13.0%
H
1.2
1.5
|
L
 -16.7%
H
1.2
1.9
|
L
 -58.2%
H
1.2
3.5
|
L
 -94.5%
H
1.2
23.4
|
L
 -99.6%
H
1.2
444
|
L
 -100.0%
H
1.2
11336448
|
Achilles Therapeutics Plc ... |
|
60.4
|
1.5
|
L
 2.1%
H
1.4
1.5
|
L
 6.5%
H
1.4
1.5
|
L
 6.5%
H
1.4
1.5
|
L
 51.6%
H
0.9
1.5
|
L
 33.6%
H
0.6
1.5
|
L
 -53.2%
H
0.6
3.5
|
L
H
0.6
19.0
|
L
H
0.6
19.0
|
Adagene Inc - ADR |
|
80.6
|
1.8
|
L
 0.6%
H
1.8
2.0
|
L
 -8.5%
H
1.8
2.1
|
L
 3.4%
H
1.8
2.3
|
L
 -11.2%
H
1.6
2.3
|
L
 -35.9%
H
1.6
3.6
|
L
 -60.4%
H
0.9
4.8
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
Addex Therapeutics Ltd - ADR |
|
7.9
|
7.4
|
L
 -4.6%
H
6.8
7.7
|
L
H
6.8
8
|
L
 -0.1%
H
6.7
9.8
|
L
 -5.8%
H
6.7
9.8
|
L
 -37.2%
H
6.7
27.9
|
L
 -92.6%
H
5
109
|
L
 -94.8%
H
5
750.4
|
L
H
5
750.4
|
Amarin Corp - ADR |
|
178.1
|
0.4
|
L
 2.4%
H
0.4
0.4
|
L
 -6.5%
H
0.4
0.5
|
L
 -29.5%
H
0.4
0.6
|
L
 -14%
H
0.4
0.7
|
L
 -50%
H
0.4
1.1
|
L
 -85.9%
H
0.4
3.7
|
L
 -95.9%
H
0.4
13.9
|
L
 -81.9%
H
0.4
26.1
|
Ascendis Pharma A/S - ADR |
|
10,038.7
|
167.1
|
L
 -1.1%
H
163.9
169.0
|
L
 20.9%
H
136.6
169.4
|
L
 16.0%
H
136.6
169.4
|
L
 19.1%
H
118.0
169.4
|
L
 12.4%
H
111.1
169.4
|
L
 41.0%
H
61.6
169.4
|
L
 70.0%
H
61.6
184.0
|
L
 835.4%
H
11.9
184.0
|
Alterity Therapeutics Ltd ... |
|
40.4
|
3.8
|
L
 -6.2%
H
3.7
4.0
|
L
 4.1%
H
3.6
4.1
|
L
 -14.5%
H
3.5
4.5
|
L
 71.0%
H
2.1
5.9
|
L
 114.8%
H
1
5.9
|
L
 -48.8%
H
1
8.7
|
L
 -14.1%
H
1
51.5
|
L
 -94.5%
H
1
111
|
Avadel Pharmaceuticals plc... |
|
841.6
|
8.7
|
L
 -1.5%
H
8.6
8.9
|
L
 14.5%
H
7.5
8.9
|
L
 1.2%
H
7.5
8.9
|
L
 -18.8%
H
7.4
11.5
|
L
 -45.3%
H
7.4
19.1
|
L
 19.0%
H
1.1
19.1
|
L
 69.5%
H
1.1
19.1
|
L
 -51.7%
H
1.0
26.1
|
Astrazeneca plc - ADR |
|
239,500.5
|
77.3
|
L
 -0.2%
H
76.7
77.5
|
L
 1.7%
H
74.2
77.8
|
L
 5.0%
H
73.5
78.4
|
L
 15.0%
H
63.8
78.4
|
L
 16.5%
H
62.8
87.7
|
L
 21.3%
H
52.7
87.7
|
L
 88.7%
H
38.1
87.7
|
L
 124.8%
H
25.6
87.7
|
Biofrontera Inc |
|
9.0
|
1.0
|
L
H
1
1.1
|
L
 14.8%
H
0.9
1.1
|
L
 -14.4%
H
0.8
1.2
|
L
 4.1%
H
0.8
1.9
|
L
 -34.8%
H
0.7
2.4
|
L
 -98.4%
H
0.6
122.4
|
L
H
0.6
292.6
|
L
H
0.6
292.6
|
Biomea Fusion Inc |
|
87.7
|
2.4
|
L
 -4.0%
H
2.4
2.6
|
L
 -3.2%
H
2.3
2.8
|
L
 -35.1%
H
2.3
4.0
|
L
 -47.8%
H
2.3
4.6
|
L
 -86.4%
H
2.3
17.9
|
L
 -55.3%
H
2.3
43.7
|
L
H
2.3
43.7
|
L
H
2.3
43.7
|
Bolt Biotherapeutics Inc |
|
15.7
|
0.4
|
L
H
0.4
0.4
|
L
H
0.4
0.5
|
L
 -18%
H
0.4
0.5
|
L
 -24.1%
H
0.4
0.6
|
L
 -63.1%
H
0.4
1.6
|
L
 -86.7%
H
0.4
3.2
|
L
H
0.4
43.1
|
L
H
0.4
43.1
|
Blue Water Biotech Inc |
|
2.1
|
0.1
|
L
 -29.4%
H
0.1
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -99.7%
H
0.1
63.5
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
BeyondSpring Inc |
|
67.3
|
1.7
|
L
 -4.6%
H
1.7
1.7
|
L
 1.2%
H
1.6
1.8
|
L
 -2.3%
H
1.6
1.9
|
L
 2.5%
H
1.4
1.9
|
L
 -43.2%
H
1.4
3.8
|
L
 -16.9%
H
0.5
4
|
L
 -85.5%
H
0.5
33
|
L
H
0.5
48.5
|
Biodexa Pharmaceuticals Pl... |
|
1.4
|
2.0
|
L
 -3.8%
H
2
2.1
|
L
 -28.4%
H
1.8
2.5
|
L
 -52.2%
H
1.8
4.7
|
L
 -51.3%
H
1.8
9.2
|
L
 -99.7%
H
1.8
1849.9
|
L
 -100.0%
H
1.8
1050000
|
L
 -100.0%
H
1.8
7070000
|
L
H
1.8
398544219.1
|
Bioline Rx Ltd - ADR |
|
11.7
|
3.3
|
L
 2.2%
H
3.1
3.3
|
L
 4.4%
H
3.0
3.3
|
L
 -11.3%
H
2.9
4.2
|
L
 -60.7%
H
0.1
14.7
|
L
 -92.9%
H
0.1
56
|
L
 -94.7%
H
0.1
101.2
|
L
 -93.5%
H
0.1
253.6
|
L
 -99.7%
H
0.1
1680
|
Belite Bio Inc - ADR |
|
2,165.8
|
68.0
|
L
 0.3%
H
67.4
68.3
|
L
 1.6%
H
65.1
71.0
|
L
 21.5%
H
54.3
71.0
|
L
 7.9%
H
52.0
71.0
|
L
 76.8%
H
31
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
Neuphoria Therapeutics Inc. |
|
8.6
|
4.9
|
L
 -1.8%
H
4.8
5.1
|
L
 -5.4%
H
4.3
5.2
|
L
 -0.6%
H
4.3
5.8
|
L
 1718.5%
H
0.2
12.6
|
L
 376.7%
H
0.2
12.6
|
L
 -42.0%
H
0.2
12.6
|
L
H
0.2
22
|
L
H
0.2
22
|
Capricor Therapeutics Inc |
|
543.8
|
12.0
|
L
 -7.1%
H
11.8
12.9
|
L
 -3.1%
H
11.8
13.9
|
L
 -25.0%
H
11.8
16.5
|
L
 -9.4%
H
11.8
16.5
|
L
 87.2%
H
3.5
23.4
|
L
 157.8%
H
2.7
23.4
|
L
 922.2%
H
1.0
23.4
|
L
 -86.1%
H
0.9
106.8
|
CASI Pharmaceuticals Inc |
|
34.9
|
2.3
|
L
 -0.4%
H
2.2
2.5
|
L
 0.5%
H
2.0
2.5
|
L
 -10%
H
2.0
2.6
|
L
 -27.9%
H
2.0
3.5
|
L
 -29.3%
H
2.0
7.7
|
L
 -72.4%
H
1.5
10.3
|
L
 -87.0%
H
1.5
39
|
L
 -84.9%
H
1.5
88.9
|
Cullinan Oncology Inc |
|
523.1
|
8.9
|
L
 -1%
H
8.4
9.1
|
L
 9.7%
H
8.0
9.4
|
L
 -6.2%
H
7.9
9.8
|
L
 -22.2%
H
7.9
13.0
|
L
 -43.9%
H
7.9
30.2
|
L
 -30.2%
H
7.3
30.2
|
L
H
7.3
59.9
|
L
H
7.3
59.9
|
Coherus Biosciences Inc |
|
102.0
|
0.9
|
L
 -4.4%
H
0.9
0.9
|
L
 -15.4%
H
0.9
1.1
|
L
 -25.4%
H
0.9
1.2
|
L
 -45%
H
0.9
1.8
|
L
 -60.4%
H
0.7
2.6
|
L
 -93.1%
H
0.7
14.1
|
L
 -93.4%
H
0.7
22.2
|
L
 -97.1%
H
0.7
38.1
|
Cingulate Inc |
|
13.4
|
3.7
|
L
 -0.5%
H
3.6
3.7
|
L
 -0.5%
H
3.5
3.9
|
L
 -18.4%
H
3.5
4.6
|
L
 -8.5%
H
3.5
5.6
|
L
 225.7%
H
0.2
20.8
|
L
 105.6%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
Checkpoint Therapeutics Inc |
|
221.6
|
4.0
|
L
 0.5%
H
4.0
4.0
|
L
 0.8%
H
4.0
4.0
|
L
 21.2%
H
2.4
4.1
|
L
 7.8%
H
2.4
4.4
|
L
 108.9%
H
1.4
4.5
|
L
 -77.8%
H
1.3
19.3
|
L
 -69.8%
H
1.3
53.8
|
L
H
1.3
150
|
Clene Inc |
|
36.7
|
4.4
|
L
 -3.3%
H
4.4
4.6
|
L
 0.2%
H
4.3
4.7
|
L
 -8.3%
H
4.1
5.0
|
L
 -4.1%
H
4.1
6.2
|
L
 -44.9%
H
3.8
9.2
|
L
 -92.2%
H
3.8
102.6
|
L
 748.1%
H
0.5
356.4
|
L
H
0.5
356.4
|
Cellectar Biosciences Inc |
|
17.5
|
0.4
|
L
 11.8%
H
0.3
0.4
|
L
 18.8%
H
0.3
0.4
|
L
 31.0%
H
0.3
0.4
|
L
 46.2%
H
0.2
0.4
|
L
 -89.1%
H
0.2
4.2
|
L
 -92.7%
H
0.2
7.9
|
L
 -96.9%
H
0.2
29.8
|
L
 -100.0%
H
0.2
3889
|
Clearside Biomedical Inc |
|
74.3
|
1.0
|
L
 10.1%
H
0.9
1.0
|
L
 11.4%
H
0.8
1.0
|
L
 -8.4%
H
0.8
1.1
|
L
 -3.9%
H
0.8
1.1
|
L
 -42.7%
H
0.8
1.8
|
L
 -64.5%
H
0.7
2.9
|
L
 -27.4%
H
0.7
7.7
|
L
H
0.6
25.1
|
Clearmind Medicine Inc |
|
5.4
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
H
1.1
1.2
|
L
 -18.4%
H
1.1
1.4
|
L
 -9.5%
H
1.1
2.2
|
L
 -9.5%
H
1.0
2.3
|
L
 -89.4%
H
0.1
17.1
|
L
 -3.4%
H
0.1
21.9
|
L
H
0.1
21.9
|
Compass Therapeutics Inc |
|
318.0
|
2.3
|
L
 -2.1%
H
2.3
2.4
|
L
 -3.0%
H
2.3
2.7
|
L
 -32.0%
H
2.3
3.6
|
L
 50.3%
H
1.3
4.1
|
L
 0.4%
H
0.8
4.1
|
L
 58.6%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
Chimerix Inc |
|
788.1
|
8.5
|
L
H
8.5
8.5
|
L
 0.1%
H
8.4
8.5
|
L
 93.4%
H
4.5
8.5
|
L
 201.4%
H
2.7
8.5
|
L
 636.5%
H
0.8
8.5
|
L
 65.1%
H
0.8
8.5
|
L
 460.9%
H
0.8
11.6
|
L
 -79.8%
H
0.8
58.0
|
Cns Pharmaceuticals Inc |
|
4.7
|
3.1
|
L
 2.3%
H
3.1
3.2
|
L
 20.4%
H
2.4
3.4
|
L
 -55.3%
H
2
8.4
|
L
 -44.1%
H
2
9.5
|
L
 -99.7%
H
2
1100
|
L
 -100.0%
H
2
33600
|
L
 -100.0%
H
2
421500
|
L
H
2
426750
|
Context Therapeutics Inc |
|
60.0
|
0.8
|
L
 -4.8%
H
0.8
0.9
|
L
 5.3%
H
0.6
0.9
|
L
 -2.4%
H
0.6
0.9
|
L
 -38.0%
H
0.6
1.4
|
L
 -26.6%
H
0.6
2.8
|
L
 -57.4%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
Cocrystal Pharma Inc |
|
16.4
|
1.6
|
L
 -3.0%
H
1.6
1.7
|
L
 -0.6%
H
1.6
1.8
|
L
 -13.0%
H
1.6
2.1
|
L
 -17.0%
H
1.6
3.3
|
L
 5.9%
H
1.4
3.3
|
L
 -75.3%
H
1.3
7.4
|
L
 -81.1%
H
1.3
41.5
|
L
 -99.6%
H
1.3
550.8
|
Collegium Pharmaceutical Inc |
|
934.2
|
29.7
|
L
H
29.3
29.8
|
L
 0.0%
H
28.6
30.0
|
L
 0.0%
H
27.3
31.4
|
L
 -4.0%
H
27.3
34.1
|
L
 -24.1%
H
27.3
42.3
|
L
 53.6%
H
14.0
42.3
|
L
 84.7%
H
13
42.3
|
L
H
7.4
42.3
|
Corcept Therapeutics Inc |
|
6,016.9
|
57.0
|
L
 -1.5%
H
56.1
57.9
|
L
 1.1%
H
54.1
58.5
|
L
 -21.6%
H
52.5
75
|
L
 3.4%
H
49
75
|
L
 145.5%
H
20.8
75
|
L
 132.4%
H
17.2
75
|
L
 449.4%
H
9.7
75
|
L
 1196.1%
H
3.2
75
|
Cosmos Health Inc |
|
11.2
|
0.5
|
L
 -4%
H
0.5
0.5
|
L
 2.1%
H
0.5
0.5
|
L
 -22.6%
H
0.4
0.7
|
L
 -31.4%
H
0.4
1.1
|
L
 -35.1%
H
0.4
1.6
|
L
 -99.3%
H
0.4
73.7
|
L
 -99.2%
H
0.4
225
|
L
 -99.6%
H
0.4
312.5
|
Cumberland Pharmaceuticals... |
|
71.4
|
5.1
|
L
 -1.2%
H
5.0
5.2
|
L
 2.4%
H
4.6
5.6
|
L
 -0.8%
H
4.6
7.3
|
L
 141.0%
H
2.1
7.3
|
L
 183.9%
H
1.0
7.3
|
L
 86.5%
H
1.0
7.3
|
L
 34.5%
H
1.0
7.5
|
L
 -25.5%
H
1.0
8.0
|
Catalyst Pharmaceuticals Inc |
|
2,680.4
|
22.1
|
L
 1.2%
H
21.5
22.1
|
L
 6.8%
H
20.2
22.1
|
L
 -5.2%
H
20.2
23.6
|
L
 -0.1%
H
19.2
24.6
|
L
 37.3%
H
14.5
24.6
|
L
 198.6%
H
6.2
24.6
|
L
 663.7%
H
2.6
24.6
|
L
 356.0%
H
0.5
24.6
|
Corbus Pharmaceuticals Hol... |
|
77.6
|
6.3
|
L
 -8.9%
H
6.3
6.9
|
L
 -6.6%
H
6.3
7.2
|
L
 -25.5%
H
6.3
8.8
|
L
 -55.6%
H
6.3
14.3
|
L
 -85.5%
H
6.3
61.9
|
L
 -50.5%
H
2.1
61.9
|
L
 -95.0%
H
2.1
293.4
|
L
 -93.0%
H
2.1
323.4
|
Crinetics Pharmaceuticals Inc |
|
3,156.2
|
33.9
|
L
 -3.6%
H
33.7
34.8
|
L
 0.5%
H
33.1
36
|
L
 -3.7%
H
31.8
37.7
|
L
 -38.7%
H
31.8
55.5
|
L
 -12.9%
H
31.8
62.5
|
L
 74.7%
H
15.2
62.5
|
L
 155.4%
H
10.7
62.5
|
L
H
10.6
62.5
|
Corvus Pharmaceuticals Inc |
|
302.7
|
4.7
|
L
 -0.2%
H
4.5
4.8
|
L
 10.8%
H
4.1
4.8
|
L
 -3.5%
H
3.8
5.0
|
L
 -36.3%
H
3.8
6.5
|
L
 147.9%
H
1.3
10
|
L
 190.7%
H
0.6
10
|
L
 147.9%
H
0.6
10
|
L
H
0.6
22.1
|
CytomX Therapeutics Inc |
|
48.1
|
0.6
|
L
 -4.8%
H
0.6
0.6
|
L
 -10.5%
H
0.6
0.7
|
L
 -25%
H
0.6
0.8
|
L
 -46.9%
H
0.6
1.2
|
L
 -71.0%
H
0.6
5.9
|
L
 -82.7%
H
0.6
5.9
|
L
 -87.0%
H
0.6
15.4
|
L
H
0.6
35
|
CureVac N.V. |
|
677.5
|
3.0
|
L
 -1.6%
H
3.0
3.1
|
L
 3.4%
H
2.9
3.2
|
L
 -17.3%
H
2.9
3.6
|
L
 4.9%
H
2.7
5
|
L
 -8.5%
H
2.2
5.3
|
L
 -84.2%
H
2.2
20.5
|
L
H
2.2
151.8
|
L
H
2.2
151.8
|
Cyclacel Pharmaceuticals Inc |
|
61.8
|
0.3
|
L
H
0.3
0.3
|
L
 -3.2%
H
0.3
0.3
|
L
 -18.9%
H
0.3
0.4
|
L
 -18.9%
H
0.3
0.9
|
L
 -87.7%
H
0.3
4
|
L
 -90.1%
H
0.2
4.4
|
L
 -95.9%
H
0.2
19.3
|
L
 -99.9%
H
0.2
264
|
Cyclerion Therapeutics Inc |
|
6.7
|
2.6
|
L
 2.8%
H
2.5
2.8
|
L
 -0.4%
H
2.5
2.8
|
L
 -16.0%
H
2.3
3.2
|
L
 -21.3%
H
2.3
6.3
|
L
 -19.4%
H
1.3
8.4
|
L
 -87.5%
H
1.3
28
|
L
 -95.5%
H
1.3
179.2
|
L
H
1.3
457
|
Cytokinetics Inc |
|
5,094.0
|
43.0
|
L
 -4.2%
H
43
44.7
|
L
 -0.7%
H
42.0
45.5
|
L
 -6.8%
H
41.9
51.7
|
L
 -10.0%
H
40.5
52.8
|
L
 -34.0%
H
40.5
75.7
|
L
 16.1%
H
26.0
110
|
L
 302.8%
H
8
110
|
L
 448.7%
H
5.5
110
|
Cellectis - ADR |
|
126.3
|
1.3
|
L
 3.3%
H
1.2
1.3
|
L
 3.3%
H
1.1
1.4
|
L
 -18.7%
H
1.1
1.6
|
L
 -25.9%
H
1.1
2.2
|
L
 -50.4%
H
1.1
3.4
|
L
 -73.0%
H
1.0
5.0
|
L
 -86.1%
H
1.0
34.7
|
L
H
1.0
50
|
Centessa Pharmaceuticals p... |
|
2,199.2
|
16.7
|
L
 -3.0%
H
16.2
17.4
|
L
 5.6%
H
15.4
18.0
|
L
 -2.3%
H
14.6
18.0
|
L
 -5.2%
H
14.4
19.1
|
L
 55.2%
H
7.8
19.1
|
L
 90.2%
H
2.9
19.1
|
L
H
2.9
26.9
|
L
H
2.9
26.9
|
Connect Biopharma Holdings... |
|
44.8
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 1.3%
H
0.8
0.9
|
L
 -12.0%
H
0.8
1.0
|
L
 -23.6%
H
0.8
1.4
|
L
 -37.7%
H
0.8
2.7
|
L
 -74.8%
H
0.5
5.0
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
Dare Bioscience Inc |
|
25.9
|
3.0
|
L
 3.5%
H
2.9
3
|
L
 1.0%
H
2.9
3.1
|
L
 -2.0%
H
2.9
3.3
|
L
 -6.6%
H
2.7
3.4
|
L
 -47.0%
H
0.3
7.6
|
L
 -84.2%
H
0.3
22.6
|
L
 -69.9%
H
0.3
46.2
|
L
 -99.7%
H
0.3
1304.4
|
Day One Biopharmaceuticals... |
|
825.0
|
8.1
|
L
 -6.1%
H
8.1
8.7
|
L
 0.9%
H
7.9
9.0
|
L
 -33.6%
H
7.9
12.6
|
L
 -35.6%
H
7.9
13.5
|
L
 -43.4%
H
7.9
18.1
|
L
 -26.4%
H
5.4
28.4
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
Journey Medical Corp |
|
112.0
|
5.4
|
L
 0.9%
H
5.2
5.4
|
L
 7.2%
H
5.0
5.5
|
L
 2.3%
H
4.9
5.8
|
L
 11.0%
H
3.5
5.8
|
L
 57.7%
H
2.9
6.9
|
L
 19.1%
H
1.0
8.1
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
Diffusion Pharmaceuticals Inc |
|
-
|
9.5
|
L
 2.2%
H
8.8
10.2
|
L
H
8.8
10.2
|
L
H
8.8
10.2
|
L
H
8.8
10.2
|
L
H
8.8
10.2
|
L
 -51.3%
H
4.1
29.7
|
L
 -55.8%
H
4.1
138.8
|
L
 -100.0%
H
4.1
34312.5
|
DiaMedica Therapeutics Inc |
|
224.1
|
5.2
|
L
 -12.5%
H
5.2
6
|
L
 -4.2%
H
5.2
6.1
|
L
 -16.7%
H
5.2
6.8
|
L
 0.8%
H
4.5
6.8
|
L
 72.9%
H
2.1
6.8
|
L
 100%
H
1.1
6.8
|
L
 72.4%
H
1.1
10.9
|
L
 227.5%
H
1
13.8
|
Dermata Therapeutics Inc |
|
6.4
|
1.2
|
L
 2.6%
H
1.2
1.2
|
L
 -4.8%
H
1.1
1.3
|
L
 0.8%
H
1.1
1.3
|
L
 13.2%
H
1
1.7
|
L
 200%
H
0.2
5.8
|
L
 -92.5%
H
0.2
23.5
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
Durect Corp |
|
24.8
|
0.8
|
L
H
0.8
0.8
|
L
H
0.8
0.9
|
L
 3.9%
H
0.7
0.9
|
L
 -11.1%
H
0.7
1.0
|
L
 -38.0%
H
0.7
1.9
|
L
 -88.1%
H
0.5
9.7
|
L
 -92.9%
H
0.5
29.6
|
L
 -95.1%
H
0.5
39.5
|
DBV Technologies - ADR |
|
100.5
|
4.9
|
L
 4.7%
H
4.8
5.1
|
L
 16.7%
H
4.2
5.3
|
L
 11.4%
H
3.8
5.3
|
L
 52.7%
H
2.7
5.4
|
L
 -38.0%
H
0.5
8.3
|
L
 -67.3%
H
0.5
34.3
|
L
 -79.0%
H
0.5
73.8
|
L
 -97.7%
H
0.5
505.7
|
Edesa Biotech Inc |
|
16.4
|
2.4
|
L
 -3.7%
H
2.4
2.5
|
L
 1.7%
H
2.3
2.6
|
L
 -12.6%
H
2
2.7
|
L
 25.7%
H
1.6
4.5
|
L
 -46.5%
H
1.6
5.6
|
L
 -90.1%
H
1.6
28.3
|
L
 -80.9%
H
1.6
133.7
|
L
 -99.9%
H
1.6
3228.1
|
Eledon Pharmaceuticals Inc |
|
214.5
|
3.6
|
L
 -1.1%
H
3.5
3.7
|
L
H
3.5
3.8
|
L
 -20.8%
H
3.5
4.7
|
L
 -19.9%
H
3.5
5.0
|
L
 133.1%
H
1.5
5.4
|
L
 4.7%
H
1.1
5.4
|
L
 -38.2%
H
1.1
27.3
|
L
 -99.8%
H
1.1
2383.0
|
Enanta Pharmaceuticals Inc |
|
129.9
|
6.1
|
L
 -0.2%
H
5.9
6.2
|
L
 -10.0%
H
5.9
7.4
|
L
 -14.7%
H
5.9
8.8
|
L
 -2.6%
H
4.7
8.8
|
L
 -57.1%
H
4.7
17.8
|
L
 -91.2%
H
4.7
79.5
|
L
 -86.1%
H
4.7
102
|
L
 -82.3%
H
4.7
127.8
|
Entera Bio Ltd |
|
71.5
|
1.9
|
L
 -0.5%
H
1.9
2.0
|
L
 9.0%
H
1.8
2.1
|
L
 -20.2%
H
1.8
2.5
|
L
 -12.6%
H
1.8
2.8
|
L
 41.6%
H
1.3
3.4
|
L
 -14.5%
H
0.5
3.4
|
L
 -4.9%
H
0.5
10.2
|
L
H
0.5
10.2
|
Evolus Inc |
|
835.5
|
13.1
|
L
 -3.3%
H
13.1
13.5
|
L
 3.6%
H
12.0
13.6
|
L
 -10.9%
H
11.9
15.1
|
L
 12.0%
H
9.3
17.1
|
L
 -5.5%
H
9.3
17.8
|
L
 16.6%
H
6.5
17.8
|
L
 222.9%
H
2.9
17.8
|
L
H
2.9
39.5
|
Essa Pharma Inc |
|
70.1
|
1.6
|
L
 -1.3%
H
1.6
1.6
|
L
 -2.5%
H
1.6
1.7
|
L
 -8.7%
H
1.6
1.8
|
L
 -3.7%
H
1.6
2.0
|
L
 -82.4%
H
1.4
9.6
|
L
 -76.6%
H
1.4
11.7
|
L
 -57.8%
H
1.4
36
|
L
 -98.2%
H
1.4
245
|
Erasca Inc |
|
410.0
|
1.5
|
L
 -0.7%
H
1.4
1.5
|
L
 1.4%
H
1.4
1.6
|
L
 -7.6%
H
1.2
1.6
|
L
 -44.9%
H
1.2
2.8
|
L
 -32.2%
H
1.2
3.5
|
L
 -87.0%
H
1.2
11.8
|
L
H
1.2
24.5
|
L
H
1.2
24.5
|
Esperion Therapeutics Inc. |
|
308.6
|
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 -1.3%
H
1.5
1.6
|
L
 -16.1%
H
1.5
1.9
|
L
 -36.6%
H
1.5
2.4
|
L
 -24.6%
H
1.5
3.9
|
L
 -69.4%
H
0.7
8.9
|
L
 -95.0%
H
0.7
53.7
|
L
 -98.4%
H
0.7
121.0
|
89bio Inc |
|
1,259.8
|
8.6
|
L
 -0.8%
H
8.2
8.7
|
L
 20.7%
H
6.9
8.8
|
L
 -18.4%
H
6.9
11.3
|
L
 8.2%
H
6.0
11.8
|
L
 -36.2%
H
6.0
13.7
|
L
 117.4%
H
2
22.9
|
L
 -49.5%
H
2
42.4
|
L
H
2
47.3
|
Eton Pharmaceuticals Inc |
|
378.5
|
14.5
|
L
 -5.0%
H
12.7
15.6
|
L
 6.1%
H
12.7
15.7
|
L
 -11.5%
H
12.7
17.1
|
L
 15.0%
H
11.6
18.4
|
L
 277.4%
H
3.0
18.4
|
L
 248.4%
H
2.0
18.4
|
L
 354.1%
H
2.0
18.4
|
L
H
2.0
18.4
|
Evoke Pharma Inc |
|
4.8
|
3.2
|
L
 -8.3%
H
3.1
3.6
|
L
 -14.9%
H
3.1
4.0
|
L
 -40.4%
H
3.1
5.3
|
L
 -30.3%
H
3.1
5.8
|
L
 -57.0%
H
0.4
12.3
|
L
 -95.8%
H
0.4
201.6
|
L
 -97.6%
H
0.4
873.0
|
L
 -99.7%
H
0.4
1599.8
|
Exelixis Inc |
|
10,190.5
|
36.4
|
L
 -1.7%
H
36.1
37.3
|
L
 -7.0%
H
36.1
39
|
L
 4.0%
H
34
40.0
|
L
 5.0%
H
31.9
40.0
|
L
 58.4%
H
20.1
40.0
|
L
 75.5%
H
14.9
40.0
|
L
 146.7%
H
13.9
40.0
|
L
 1248.5%
H
2.5
40.0
|
Eyenovia Inc |
|
3.5
|
1.7
|
L
 -2.3%
H
1.6
1.7
|
L
 7.1%
H
1.5
1.8
|
L
 -13.0%
H
1.4
2.0
|
L
 -76.3%
H
0.0
18.0
|
L
 -98.7%
H
0.0
131.1
|
L
 -99.3%
H
0.0
468
|
L
 -99.0%
H
0.0
617.6
|
L
H
0.0
859.2
|
EyePoint Pharmaceuticals Inc |
|
428.2
|
6.2
|
L
 -6.0%
H
6.2
6.6
|
L
 -12.1%
H
6.2
7.6
|
L
 -4.2%
H
5.5
7.6
|
L
 -22.3%
H
5.5
9.5
|
L
 -71%
H
5.5
24.0
|
L
 -52.2%
H
2.2
31.0
|
L
 -42.8%
H
2.2
31.0
|
L
 -85.7%
H
2.2
58.1
|
Evotec SE - ADR |
|
1,299.7
|
3.7
|
L
 2.0%
H
3.6
3.7
|
L
 4.3%
H
3.4
3.7
|
L
 -20.1%
H
3.4
4.7
|
L
 -23.1%
H
3.4
5.1
|
L
 -46.9%
H
2.9
8.0
|
L
 -75.9%
H
2.9
16.5
|
L
 -66.6%
H
2.9
26.6
|
L
 85.8%
H
1.6
26.6
|
Fortress Biotech Inc |
|
47.2
|
1.7
|
L
 -2.3%
H
1.7
1.8
|
L
 -1.7%
H
1.6
1.8
|
L
H
1.5
1.8
|
L
 -6.0%
H
1.5
2.4
|
L
 -11.9%
H
1.4
2.9
|
L
 -92.0%
H
1.2
23.0
|
L
 -91.7%
H
1.2
91.5
|
L
 -96.5%
H
1.2
91.5
|
Fennec Pharmaceuticals Inc |
|
178.5
|
6.5
|
L
 3.5%
H
6.4
6.6
|
L
 7.0%
H
5.9
6.6
|
L
 -2.1%
H
5.8
7.1
|
L
 7.7%
H
5.5
7.1
|
L
 -34.2%
H
4.0
11.5
|
L
 21.6%
H
4.0
11.9
|
L
 22.9%
H
3.8
11.9
|
L
 149.6%
H
0.3
15.0
|
FibroGen Inc |
|
37.3
|
0.4
|
L
 -15.9%
H
0.3
0.4
|
L
 -2.6%
H
0.3
0.5
|
L
 -33.9%
H
0.3
0.9
|
L
 5.7%
H
0.3
0.9
|
L
 -82.3%
H
0.2
2.8
|
L
 -97.2%
H
0.2
25.7
|
L
 -98.6%
H
0.2
57.2
|
L
 -98.8%
H
0.2
68.6
|
Q32 Bio Inc. |
|
27.0
|
2.2
|
L
 0.9%
H
2.1
2.3
|
L
 7.3%
H
1.8
2.3
|
L
 -17.2%
H
1.8
2.8
|
L
 -35.6%
H
1.8
4.2
|
L
 -86.6%
H
1.8
53.8
|
L
 -96.5%
H
1.8
64.3
|
L
 -99.1%
H
1.8
349.1
|
L
H
1.8
572.4
|
Amicus Therapeutics Inc |
|
2,802.0
|
9.1
|
L
H
9
9.2
|
L
 5.7%
H
8.6
9.2
|
L
 -6.7%
H
8.5
10
|
L
 -7.8%
H
8.5
10
|
L
 -20.6%
H
8.5
12.7
|
L
 -6.8%
H
5.9
14.6
|
L
 6.9%
H
5.9
25.4
|
L
 -4.9%
H
4.4
25.4
|
Fulcrum Therapeutics Inc |
|
163.0
|
3.0
|
L
 -3.2%
H
3.0
3.1
|
L
 1.7%
H
2.8
3.2
|
L
 -18.2%
H
2.8
3.9
|
L
 -33.5%
H
2.8
5.2
|
L
 -73.4%
H
2.8
11.5
|
L
 -82.7%
H
2.3
24.8
|
L
 -74.1%
H
2.3
33.1
|
L
H
2.3
33.1
|
Generation Bio Co |
|
38.7
|
0.6
|
L
 9.4%
H
0.5
0.6
|
L
 16%
H
0.5
0.6
|
L
 -14.7%
H
0.5
0.8
|
L
 -47.3%
H
0.5
1.3
|
L
 -81.2%
H
0.5
4.7
|
L
 -89.6%
H
0.5
9.6
|
L
H
0.5
55.7
|
L
H
0.5
55.7
|
GH Research PLC |
|
639.5
|
10.3
|
L
 -3.2%
H
10.2
10.9
|
L
 -8.0%
H
10.2
11.8
|
L
 -28.0%
H
8.6
14.6
|
L
 21.9%
H
6.7
20.5
|
L
 -5.4%
H
6
20.5
|
L
 -37.9%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
Galmed Pharmaceuticals Ltd |
|
4.0
|
2.4
|
L
 -7.9%
H
2.2
2.5
|
L
 28.4%
H
1.7
3.5
|
L
 -6.9%
H
1.7
3.5
|
L
 -18.9%
H
1.7
3.6
|
L
 -33.3%
H
0.2
13.6
|
L
 -99.1%
H
0.2
330.9
|
L
 -99.6%
H
0.2
1132.2
|
L
 -99.9%
H
0.2
4870.8
|
Galecto Inc |
|
5.5
|
4.2
|
L
 2.2%
H
4.1
4.3
|
L
 3.2%
H
3.8
4.3
|
L
 -12.8%
H
3.8
5
|
L
 -18.2%
H
3.8
6.0
|
L
 408.5%
H
0.5
14.8
|
L
 94.0%
H
0.5
14.8
|
L
H
0.5
18.0
|
L
H
0.5
18.0
|
GlycoMimetics Inc |
|
17.4
|
0.3
|
L
H
0.3
0.3
|
L
 3.9%
H
0.2
0.3
|
L
 -6.9%
H
0.2
0.4
|
L
 17.4%
H
0.2
0.4
|
L
 -89.5%
H
0.1
3.2
|
L
 -76.7%
H
0.1
4.2
|
L
 -87.8%
H
0.1
5.2
|
L
 -96.8%
H
0.1
26.1
|
Genelux Corp |
|
125.4
|
3.6
|
L
 -2.7%
H
3.5
3.9
|
L
 -4.0%
H
3.3
3.9
|
L
 -32.0%
H
3.3
5.4
|
L
 52.5%
H
2.2
5.9
|
L
 -42.0%
H
1.6
6.5
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
Genprex Inc |
|
3.1
|
0.4
|
L
 -7.5%
H
0.4
0.5
|
L
 12.1%
H
0.3
0.5
|
L
 -15.9%
H
0.3
0.5
|
L
 -63.7%
H
0.3
1.0
|
L
 -90.8%
H
0.3
4.5
|
L
 -83.8%
H
0.2
8.0
|
L
 -88.9%
H
0.2
8.0
|
L
H
0.2
19.5
|
Gossamer Bio Inc |
|
324.9
|
1.4
|
L
 2.9%
H
1.3
1.4
|
L
 24.4%
H
1.1
1.5
|
L
 9.2%
H
1.1
1.6
|
L
 64.4%
H
0.8
1.6
|
L
 -2.1%
H
0.5
1.6
|
L
 -84.1%
H
0.5
15.2
|
L
 -84.3%
H
0.5
16.8
|
L
H
0.5
27.2
|
GT Biopharma Inc |
|
6.1
|
2.4
|
L
 0.8%
H
2.3
2.5
|
L
 -2.8%
H
2.3
2.7
|
L
 13.1%
H
2.0
3.1
|
L
 -2.8%
H
1.7
4.1
|
L
 -47.7%
H
1.7
10.7
|
L
 -18.5%
H
0.2
10.7
|
L
 -16.3%
H
0.2
19.7
|
L
 -100.0%
H
0.2
89250
|
Genmab - ADR |
|
13,002.4
|
20.5
|
L
 -1.6%
H
20.4
20.6
|
L
 -6.9%
H
19.8
21.1
|
L
 -3.9%
H
19.8
24.3
|
L
 2.2%
H
18.6
24.3
|
L
 -31.7%
H
18.6
31.0
|
L
 -43.9%
H
18.6
47.5
|
L
 14.6%
H
16.7
49.1
|
L
 170.3%
H
6.8
49.1
|
Genfit - ADR |
|
181.7
|
3.6
|
L
H
3.6
3.7
|
L
 0.3%
H
3.5
3.7
|
L
 -11.9%
H
3.1
4.0
|
L
 -0.6%
H
3.1
4.3
|
L
 3.4%
H
3.1
6.4
|
L
 -5.2%
H
2.9
6.4
|
L
 -67.5%
H
2.9
22.5
|
L
H
2.9
26.3
|
Genenta Science SpA - ADR |
|
69.3
|
3.8
|
L
 -2.8%
H
3.7
3.8
|
L
 -0.3%
H
3.6
4.2
|
L
 -13.3%
H
3.6
4.8
|
L
 -26.0%
H
3.5
5.7
|
L
 -2.8%
H
2.2
7.3
|
L
 -39.6%
H
2.2
9.3
|
L
H
2.2
13.1
|
L
H
2.2
13.1
|
Grifols SA - ADR - Level III |
|
5,524.9
|
8.1
|
L
 0.3%
H
8.0
8.1
|
L
 4.1%
H
7.4
8.2
|
L
 10.9%
H
7.0
8.8
|
L
 0.9%
H
6.6
8.8
|
L
 32.5%
H
5.8
10.0
|
L
 -27.7%
H
5.3
13.3
|
L
 -54.0%
H
5.3
21.9
|
L
 -50.7%
H
5.3
25.7
|
Hepion Pharmaceuticals Inc |
|
0.6
|
0.8
|
L
 -19.2%
H
0.7
0.9
|
L
 -76.8%
H
0.7
5.0
|
L
 -90.8%
H
0.7
9.7
|
L
 -96.8%
H
0.7
36.7
|
L
 -99.3%
H
0.7
145
|
L
 -99.9%
H
0.7
1330
|
L
 -99.9%
H
0.7
4830
|
L
 -100.0%
H
0.7
3516800
|
Hoth Therapeutics Inc |
|
14.1
|
1.1
|
L
 -8.6%
H
1.1
1.2
|
L
 -2.7%
H
1.1
1.2
|
L
 -5.3%
H
0.8
1.3
|
L
 30.5%
H
0.7
3.8
|
L
 -7.8%
H
0.6
3.8
|
L
 -93.2%
H
0.6
40.7
|
L
 -98.5%
H
0.6
175
|
L
H
0.6
347
|
Werewolf Therapeutics Inc |
|
52.0
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -4.9%
H
1.1
1.3
|
L
 -22.2%
H
1.0
1.6
|
L
 -29.3%
H
1.0
1.7
|
L
 -81.1%
H
1.0
6.9
|
L
 -74.9%
H
1.0
8.2
|
L
H
1.0
24.0
|
L
H
1.0
24.0
|
Harmony Biosciences Holdin... |
|
1,975.6
|
34.5
|
L
 0.4%
H
34.0
34.5
|
L
 0.1%
H
32.1
34.5
|
L
 -11.6%
H
31.7
39.5
|
L
 3.1%
H
31.7
40.9
|
L
 7.7%
H
28.1
41.6
|
L
 -30.9%
H
18.6
62.1
|
L
H
18.6
62.1
|
L
H
18.6
62.1
|
Harrow Health Inc |
|
943.1
|
26.5
|
L
 13.6%
H
25.7
31.7
|
L
 19.2%
H
21.7
31.7
|
L
 -13.0%
H
21.1
31.7
|
L
 -24.5%
H
21.1
37.5
|
L
 152.4%
H
9.3
59.2
|
L
 267.3%
H
5.4
59.2
|
L
 584.2%
H
3.3
59.2
|
L
 231%
H
1.4
59.2
|
HUTCHMED (China) Limited -... |
|
2,547.0
|
14.9
|
L
 -1.6%
H
14.6
14.9
|
L
 -3.4%
H
14.6
15.8
|
L
 8.0%
H
13.6
17.1
|
L
 0.3%
H
12.8
17.1
|
L
 -15.4%
H
12.8
21.9
|
L
 -22.1%
H
7.4
21.9
|
L
 -19.0%
H
7.4
43.9
|
L
H
7.4
43.9
|
ImmunityBio Inc |
|
2,381.1
|
2.8
|
L
 -4.1%
H
2.7
2.9
|
L
 -4.1%
H
2.7
3.0
|
L
 -22.9%
H
2.7
4.3
|
L
 -1.4%
H
2.3
4.3
|
L
 -45.6%
H
2.3
10.5
|
L
 -52.7%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
Ideaya Biosciences Inc |
|
1,611.6
|
18.4
|
L
 -3.8%
H
18.3
19.0
|
L
 5.0%
H
17.0
19.6
|
L
 -12.3%
H
17.0
22.4
|
L
 -29.9%
H
17.0
27.2
|
L
 -58.4%
H
17.0
46.4
|
L
 46.9%
H
8.1
47.7
|
L
 507.6%
H
3.1
47.7
|
L
H
3.0
47.7
|
IGM Biosciences Inc |
|
72.3
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -9.7%
H
1.2
1.4
|
L
 -15.4%
H
1.2
1.6
|
L
 -83.8%
H
1.2
7.6
|
L
 -88.6%
H
1.2
22.5
|
L
 -92.4%
H
1.2
36.0
|
L
 -96.7%
H
1.2
133
|
L
H
1.2
133
|
Inhibikase Therapeutics Inc |
|
171.5
|
2.4
|
L
H
2.3
2.4
|
L
 18.6%
H
1.9
2.4
|
L
 0.4%
H
1.9
3.3
|
L
 -36.9%
H
1.9
4.2
|
L
 11.9%
H
1.1
4.2
|
L
 -70.0%
H
0.8
9.1
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
Immix Biopharma Inc |
|
51.7
|
1.9
|
L
 8.7%
H
1.7
1.9
|
L
 20.5%
H
1.6
1.9
|
L
 -5.1%
H
1.5
2
|
L
 -13.0%
H
1.5
2.5
|
L
 -28.8%
H
1.3
3.4
|
L
 -19.3%
H
0.7
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
Immuneering Corp - Ordinar... |
|
51.9
|
1.7
|
L
 -0.6%
H
1.6
1.7
|
L
 14.4%
H
1.4
1.7
|
L
 -10.2%
H
1.4
1.9
|
L
 -3.5%
H
1.4
3.8
|
L
 -12.6%
H
1
3.8
|
L
 -76.1%
H
1
16.2
|
L
H
1
34.0
|
L
H
1
34.0
|
Immunic Inc |
|
100.0
|
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 1.8%
H
1.1
1.2
|
L
 11%
H
1
1.4
|
L
 0.9%
H
0.9
1.4
|
L
 -15.3%
H
0.9
2.1
|
L
 -90.6%
H
0.9
12.6
|
L
 -78.9%
H
0.9
28.2
|
L
 -99.9%
H
0.9
1186.8
|
Incyte Corp. |
|
11,663.7
|
60.3
|
L
 -2.8%
H
58.5
61.0
|
L
 -15.3%
H
58.5
71.7
|
L
 -14.4%
H
58.5
76.2
|
L
 -13.2%
H
58.5
77.0
|
L
 3.3%
H
50.4
84.0
|
L
 -18.9%
H
50.3
86.3
|
L
 -14.4%
H
50.3
110.4
|
L
 -34.7%
H
50.3
153.2
|
Indaptus Therapeutics Inc |
|
12.1
|
0.9
|
L
 6.2%
H
0.7
1.7
|
L
 4.9%
H
0.7
1.7
|
L
 7.5%
H
0.7
1.7
|
L
 -5.5%
H
0.7
1.7
|
L
 -54.0%
H
0.7
3.1
|
L
 -76.4%
H
0.7
4.3
|
L
 -94.5%
H
0.7
63.3
|
L
 -97.3%
H
0.7
8800
|
Indivior Plc |
|
1,206.7
|
9.7
|
L
 -3.1%
H
9.6
10.0
|
L
 1.7%
H
9.2
10.1
|
L
 -1.5%
H
7.6
11.3
|
L
 -18.3%
H
7.6
12.8
|
L
 -53.3%
H
7.3
22.5
|
L
 161.6%
H
3
26.5
|
L
 1660%
H
0.5
26.5
|
L
 270.9%
H
0.4
26.5
|
InMed Pharmaceuticals Inc |
|
3.4
|
2.8
|
L
 1.8%
H
2.7
2.8
|
L
 10.3%
H
2.5
2.9
|
L
 -11.7%
H
2.5
3.5
|
L
 -46.2%
H
2.5
8.3
|
L
 -61.3%
H
2.4
15.7
|
L
 -99.2%
H
2.4
710
|
L
 -99.9%
H
2.4
5214
|
L
 -99.9%
H
2.4
32175
|
Inovio Pharmaceuticals Inc |
|
74.4
|
2.1
|
L
 -2.4%
H
2.0
2.1
|
L
 5.6%
H
1.9
2.2
|
L
 -4.2%
H
1.8
2.3
|
L
 5.1%
H
1.7
2.4
|
L
 -80.8%
H
1.7
14.8
|
L
 -41.6%
H
0.3
14.8
|
L
 -71.9%
H
0.3
33.8
|
L
 -75.9%
H
0.3
33.8
|
Insmed Inc |
|
14,020.2
|
77.5
|
L
 -0.4%
H
75.8
77.5
|
L
 6.0%
H
71.8
78.2
|
L
 -2.3%
H
71.6
84.9
|
L
 4.9%
H
61.5
84.9
|
L
 201.2%
H
21.9
84.9
|
L
 235.0%
H
16.0
84.9
|
L
 399.7%
H
12.6
84.9
|
L
 261.5%
H
9.0
84.9
|
Innoviva Inc |
|
1,092.4
|
17.4
|
L
 -0.6%
H
17.3
17.6
|
L
 -0.3%
H
17
17.9
|
L
 -3.6%
H
17
18.6
|
L
 -5.1%
H
17
19.4
|
L
 17.3%
H
14.3
21.3
|
L
 -9.5%
H
10.6
21.3
|
L
 76.2%
H
7.6
21.3
|
L
 -3.7%
H
6.4
21.3
|
Inozyme Pharma Inc |
|
62.3
|
1.0
|
L
 -4.9%
H
0.9
1.0
|
L
 -8.5%
H
0.9
1.1
|
L
 -29.2%
H
0.9
1.4
|
L
 -66.6%
H
0.9
3.2
|
L
 -83.5%
H
0.9
7.8
|
L
 -77.3%
H
0.9
7.8
|
L
H
0.9
31.7
|
L
H
0.9
31.7
|
Ionis Pharmaceuticals Inc |
|
5,257.0
|
33.1
|
L
 -3.6%
H
33.0
34.1
|
L
 2.6%
H
31.5
34.7
|
L
 6.5%
H
30.9
35
|
L
 -12.2%
H
30.2
37.9
|
L
 -22.3%
H
30.2
52.3
|
L
 -4.9%
H
30.2
54.4
|
L
 -25.7%
H
25.0
64.4
|
L
 -54.1%
H
19.6
86.6
|
Ironwood Pharmaceuticals I... |
|
235.2
|
1.5
|
L
 -4.6%
H
1.4
1.5
|
L
 2.8%
H
1.3
1.6
|
L
 -23.4%
H
1.3
2.1
|
L
 -58.4%
H
1.3
5.1
|
L
 -83.7%
H
1.3
9.2
|
L
 -88.3%
H
1.3
15.7
|
L
 -84.7%
H
1.3
15.7
|
L
 -88.9%
H
1.3
17.7
|
Intra-Cellular Therapies Inc |
|
13,976.8
|
131.5
|
L
H
131.4
131.5
|
L
 0.2%
H
131.2
131.5
|
L
 2.8%
H
127.9
131.5
|
L
 51.2%
H
80.8
131.5
|
L
 102.9%
H
63.9
131.5
|
L
 117.7%
H
42.0
131.5
|
L
 874.4%
H
10.9
131.5
|
L
 436.7%
H
6.8
131.5
|
Iterum Therapeutics Plc |
|
48.1
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 6.1%
H
1.3
1.4
|
L
 -9.7%
H
1.3
1.6
|
L
 -24.0%
H
1.3
2.1
|
L
 -4.8%
H
0.8
3.0
|
L
 -76.4%
H
0.6
7.1
|
L
 -94.5%
H
0.6
90.3
|
L
H
0.6
195
|
I-Mab - ADR |
|
69.3
|
0.9
|
L
H
0.8
0.9
|
L
 4.9%
H
0.8
0.9
|
L
 -11.5%
H
0.8
1
|
L
 -10.5%
H
0.8
1.4
|
L
 -54.3%
H
0.8
2
|
L
 -94.9%
H
0.8
21.4
|
L
 -92.6%
H
0.8
85.4
|
L
H
0.8
85.4
|
Immuron Limited - ADR |
|
9.8
|
1.7
|
L
 -6.0%
H
1.7
1.8
|
L
 -3.9%
H
1.7
2.0
|
L
 -16.2%
H
1.7
2.1
|
L
 -20.5%
H
1.7
2.5
|
L
 -40.4%
H
1.7
3.1
|
L
 -44.1%
H
1.4
6.0
|
L
 -6.6%
H
1.4
29.0
|
L
H
1.4
29.0
|
Innate Pharma - ADR |
|
171.0
|
2.0
|
L
 1.0%
H
2
2.0
|
L
 -1.0%
H
1.9
2.1
|
L
 5.2%
H
1.9
2.6
|
L
 -5.1%
H
1.6
2.6
|
L
 -19.1%
H
1.3
3.5
|
L
 -40.5%
H
1.3
4.0
|
L
 -46.3%
H
1.3
12.0
|
L
H
1.3
12.0
|
Jaguar Health Inc |
|
4.4
|
0.3
|
L
 -42.6%
H
0.3
0.4
|
L
 -50.9%
H
0.3
0.6
|
L
 -70%
H
0.3
1.0
|
L
 -71.3%
H
0.3
1.3
|
L
 -99.9%
H
0.3
1296
|
L
 -100.0%
H
0.3
220050
|
L
 -100.0%
H
0.3
3620696.0
|
L
H
0.3
400302000
|
Jazz Pharmaceuticals plc |
|
8,424.8
|
138.7
|
L
 -1.1%
H
138.3
140.9
|
L
 0.9%
H
134.0
140.9
|
L
 3.6%
H
132.6
148.1
|
L
 13.0%
H
118.7
148.1
|
L
 14.7%
H
99.1
148.1
|
L
 -11.9%
H
99.1
170.0
|
L
 31.1%
H
86.9
189
|
L
 -24.0%
H
86.9
194.7
|
Kineta Inc |
|
3.8
|
0.3
|
L
 -6.1%
H
0.3
0.3
|
L
 -11.4%
H
0.3
0.4
|
L
 -38%
H
0.3
0.5
|
L
 -39.2%
H
0.3
0.5
|
L
 -42.6%
H
0.3
1.2
|
L
 -95.6%
H
0.3
17.4
|
L
 -99.8%
H
0.3
273
|
L
H
0.3
2888.2
|
Kala Pharmaceuticals Inc |
|
43.0
|
7.1
|
L
 0.9%
H
6.9
7.3
|
L
 4.1%
H
6.5
7.3
|
L
 -15.8%
H
6.4
8.4
|
L
 14.1%
H
5.7
11.2
|
L
 -6.2%
H
4.2
11.2
|
L
 -92.0%
H
3.5
93.5
|
L
 -97.9%
H
3.5
734
|
L
H
3.5
1337.5
|
KalVista Pharmaceuticals Inc |
|
611.5
|
12.3
|
L
 -1.5%
H
11.8
12.5
|
L
 2.6%
H
11.8
12.9
|
L
 26.0%
H
9.6
12.9
|
L
 42.2%
H
7.3
12.9
|
L
 3.1%
H
7.3
15.5
|
L
 -19.9%
H
4.1
17.1
|
L
 63.1%
H
4.1
45
|
L
H
4.1
129.1
|
Kiniksa Pharmaceuticals Lt... |
|
1,632.3
|
22.5
|
L
 -2.2%
H
22.4
23.0
|
L
 7.7%
H
20.4
23.1
|
L
 13.8%
H
19.2
23.1
|
L
 9.7%
H
17.8
23.1
|
L
 12.4%
H
16.6
28.2
|
L
 107.1%
H
7.4
28.2
|
L
 81.2%
H
7.4
28.7
|
L
H
5.0
32.9
|
Kiora Pharmaceuticals Inc |
|
9.8
|
3.3
|
L
 -1.2%
H
3.3
3.3
|
L
 1.9%
H
3.1
3.4
|
L
 -10.2%
H
2.9
3.8
|
L
 -10.7%
H
2.9
4.1
|
L
 407.8%
H
0.4
5.6
|
L
 -89.6%
H
0.4
32.0
|
L
 -97.9%
H
0.4
327.2
|
L
 -99.9%
H
0.4
21000
|
Karyopharm Therapeutics Inc |
|
48.7
|
5.8
|
L
 -5.7%
H
5.6
6.1
|
L
 -24.4%
H
5.6
8.5
|
L
 -37.4%
H
0.6
10.4
|
L
 -42.1%
H
0.6
12.5
|
L
 -74.4%
H
0.6
24.8
|
L
 -94.4%
H
0.6
129.5
|
L
 -97.8%
H
0.6
389.7
|
L
 -98.9%
H
0.6
534.8
|
Kronos Bio Inc |
|
58.5
|
1.0
|
L
 2.1%
H
0.9
1.0
|
L
 2.1%
H
0.9
1.0
|
L
 -4.9%
H
0.9
1.0
|
L
 2.1%
H
0.9
1.1
|
L
 -16.4%
H
0.7
1.6
|
L
 -87.9%
H
0.7
8.4
|
L
H
0.7
39.6
|
L
H
0.7
39.6
|
Keros Therapeutics Inc |
|
458.8
|
11.3
|
L
 -2.7%
H
11.3
11.6
|
L
 3.6%
H
10.6
11.9
|
L
 9.6%
H
10.3
12.3
|
L
 -37.5%
H
9.8
18.3
|
L
 -83.2%
H
9.8
72.4
|
L
 -79.2%
H
9.8
73
|
L
H
9.8
88.8
|
L
H
9.8
88.8
|
Pasithea Therapeutics Corp |
|
1.4
|
1.1
|
L
 -3.5%
H
1.1
1.1
|
L
 -1.8%
H
1.0
1.2
|
L
 -24.8%
H
0.9
1.5
|
L
 -59.0%
H
0.9
3.9
|
L
 -84.4%
H
0.9
9.3
|
L
 -18.0%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Kazia Therapeutics Limited... |
|
5.3
|
1.0
|
L
 -5%
H
0.9
1.0
|
L
H
0.9
1.1
|
L
 6.7%
H
0.8
1.4
|
L
 -72.1%
H
0.8
3.4
|
L
 -57.6%
H
0.5
15.8
|
L
 -98.5%
H
0.5
86.1
|
L
 -97.1%
H
0.5
158.5
|
L
 -99.2%
H
0.5
378.5
|
Lexaria Bioscience Corp |
|
24.6
|
1.4
|
L
 -4.8%
H
1.3
1.7
|
L
 4.5%
H
1.3
1.7
|
L
 -12.5%
H
1.2
1.7
|
L
 -34.9%
H
1.2
2.4
|
L
 -64.1%
H
1.2
4.4
|
L
 -51.7%
H
0.7
6.9
|
L
 -83.3%
H
0.7
15.6
|
L
 -35.8%
H
0.7
76.2
|
Lifecore Biomedical Inc |
|
243.3
|
6.6
|
L
 0.3%
H
6.4
6.6
|
L
 6.5%
H
6.0
6.9
|
L
 7.9%
H
5.4
6.9
|
L
 -12.4%
H
5.4
7.8
|
L
 -11.0%
H
3.7
8.0
|
L
 -39.8%
H
1.5
12.0
|
L
 -29.6%
H
1.5
12.9
|
L
 -52.5%
H
1.5
15.6
|
Ligand Pharmaceuticals, In... |
|
2,064.6
|
107.2
|
L
 -2.5%
H
103.5
108.1
|
L
 -1.9%
H
103.4
113.0
|
L
 -10.7%
H
103.4
123.5
|
L
 -11.0%
H
102.8
123.5
|
L
 50.8%
H
67.7
129.9
|
L
 51.9%
H
46.8
129.9
|
L
 110.1%
H
42.6
141.8
|
L
 125.8%
H
36.9
179.8
|
Atyr Pharma Inc |
|
346.5
|
3.9
|
L
 -2.7%
H
3.9
4.2
|
L
 25.8%
H
3.0
4.3
|
L
 14.4%
H
2.7
4.7
|
L
 26.6%
H
2.7
4.7
|
L
 96.0%
H
1.4
4.7
|
L
 -24.0%
H
1.1
6.6
|
L
 63.9%
H
1.1
13.1
|
L
H
1.1
396.1
|
Lipella Pharmaceuticals Inc |
|
2.7
|
2.3
|
L
 1.8%
H
2.2
2.3
|
L
 3.2%
H
2.0
2.3
|
L
 -42.0%
H
2.0
3.9
|
L
 -18.5%
H
2.0
7.3
|
L
 -63.9%
H
2.0
12
|
L
H
0
61.8
|
L
H
0
61.8
|
L
H
0
61.8
|
Lipocine Inc |
|
18.5
|
3.5
|
L
 -1.4%
H
3.4
3.6
|
L
 7.8%
H
3.0
3.6
|
L
 -5.0%
H
2.9
3.7
|
L
 -33.8%
H
2.9
5.5
|
L
 -25%
H
2.9
11.8
|
L
 -86.6%
H
2.3
32.1
|
L
 -36.6%
H
2.3
41.1
|
L
 -97.3%
H
2.3
326.9
|
Liquidia Corp |
|
1,252.6
|
14.8
|
L
 0.1%
H
14.4
15.0
|
L
 7.0%
H
13.5
15.0
|
L
 -8.6%
H
13.5
16.8
|
L
 30.9%
H
10.4
16.8
|
L
 -6.9%
H
8.3
17.0
|
L
 119.6%
H
3.3
17.0
|
L
 289.5%
H
2.3
17.0
|
L
H
2.3
38.5
|
Lisata Therapeutics Inc |
|
19.7
|
2.3
|
L
 -4.2%
H
2.2
2.3
|
L
 -2.2%
H
2.1
2.6
|
L
 -9.2%
H
2.1
2.7
|
L
 -13.6%
H
2.1
4.2
|
L
 -26.0%
H
2.1
4.2
|
L
 -77.6%
H
2.0
11.9
|
L
 -90.1%
H
2.0
73.4
|
L
 -99.6%
H
2.0
535.5
|
Lantern Pharma Inc |
|
42.0
|
3.9
|
L
 -1.0%
H
3.7
3.9
|
L
 11.5%
H
3.4
4.0
|
L
 -22.4%
H
3.4
5.2
|
L
 12.1%
H
3.0
6.1
|
L
 -55.3%
H
2.8
12.0
|
L
 -44.3%
H
2.4
12.0
|
L
H
2.4
24.8
|
L
H
2.4
24.8
|
Lexicon Pharmaceuticals Inc |
|
130.1
|
0.4
|
L
 -5.3%
H
0.4
0.4
|
L
H
0.3
0.4
|
L
 -53.9%
H
0.3
1.0
|
L
 -50.7%
H
0.3
1.1
|
L
 -86.2%
H
0.3
2.6
|
L
 -83.6%
H
0.3
3.8
|
L
 -84.7%
H
0.3
9.7
|
L
 -95.4%
H
0.3
19.6
|
Lyra Therapeutics Inc |
|
10.5
|
0.2
|
L
H
0.2
0.2
|
L
 -11.1%
H
0.2
0.2
|
L
 -23.8%
H
0.2
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -97.3%
H
0.2
6.8
|
L
 -96.2%
H
0.2
8.2
|
L
H
0.2
22
|
L
H
0.2
22
|
Legend Biotech Corp - ADR |
|
6,923.6
|
37.7
|
L
 -0.6%
H
37.3
38.3
|
L
 10.8%
H
33.8
38.8
|
L
 3.5%
H
32.8
40
|
L
 12.7%
H
30.2
40
|
L
 -41.1%
H
30.2
65.5
|
L
 -3.3%
H
30.2
77.3
|
L
H
23.4
77.3
|
L
H
23.4
77.3
|
Mustang Bio Inc |
|
3.9
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 -6.7%
H
1.4
1.6
|
L
 -50%
H
1.4
3.1
|
L
 -84.2%
H
0.1
21.9
|
L
 -97.1%
H
0.1
67
|
L
 -99.8%
H
0.1
877.5
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
Moleculin Biotech Inc |
|
13.0
|
1.1
|
L
 -4.4%
H
1.0
1.2
|
L
 -6.1%
H
1.0
1.3
|
L
 -50.5%
H
0.9
2.2
|
L
 -41.9%
H
0.4
3.7
|
L
 -85.4%
H
0.4
132.8
|
L
 -95.0%
H
0.4
132.8
|
L
 -97.7%
H
0.4
177.3
|
L
H
0.4
862.2
|
Madrigal Pharmaceuticals Inc |
|
7,482.3
|
338.9
|
L
 -1.0%
H
331.1
343.6
|
L
 3.0%
H
315.0
350
|
L
 0.5%
H
299.6
377.5
|
L
 10.7%
H
266.4
377.5
|
L
 25.3%
H
189
377.5
|
L
 245.3%
H
57.2
377.5
|
L
 376.1%
H
52.3
377.5
|
L
 313.8%
H
5.3
377.5
|
MediWound Ltd |
|
205.4
|
19.0
|
L
 -0.3%
H
19.0
19.4
|
L
 14.8%
H
16.5
19.4
|
L
 1.5%
H
15.8
19.4
|
L
 11.4%
H
15.8
20.6
|
L
 19%
H
12.8
24
|
L
 42.4%
H
7.1
24
|
L
 42.4%
H
7.1
43.5
|
L
 -61.7%
H
7.1
73.3
|
MEI Pharma Inc |
|
15.5
|
2.3
|
L
 0.4%
H
2.3
2.3
|
L
 -4.5%
H
2.3
2.4
|
L
 -13.4%
H
2.3
2.8
|
L
 -10.4%
H
2.3
2.9
|
L
 -39.2%
H
2.3
4.2
|
L
 -93.8%
H
2.3
38.8
|
L
 -87.7%
H
2.3
91.5
|
L
 -98.1%
H
2.3
130
|
Macrogenics Inc |
|
129.3
|
2.1
|
L
 -5.5%
H
2.0
2.2
|
L
 -8.0%
H
2.0
2.5
|
L
 -19.5%
H
2.0
3.0
|
L
 -35.2%
H
2.0
3.6
|
L
 -87.1%
H
2.0
19.5
|
L
 -76.9%
H
2.0
21.9
|
L
 -56.2%
H
2.0
36.5
|
L
 -94.2%
H
2.0
39.9
|
Mangoceuticals Inc |
|
17.4
|
3.5
|
L
 -3.9%
H
3.2
3.8
|
L
 -28.7%
H
3.2
4.9
|
L
 -27.7%
H
3.2
6.2
|
L
 35.7%
H
2.1
6.2
|
L
 1844.4%
H
0.2
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
Magenta Therapeutics Inc |
|
-
|
20.6
|
L
 83.7%
H
20.4
22.6
|
L
H
20.4
22.6
|
L
H
20.4
22.6
|
L
H
20.4
22.6
|
L
H
20.4
22.6
|
L
 -58.8%
H
5.1
57.9
|
L
 -87.1%
H
5.1
227.2
|
L
H
5.1
336
|
Mirum Pharmaceuticals Inc |
|
2,195.8
|
44.8
|
L
 -0.8%
H
44.1
45.4
|
L
 4.2%
H
42.8
46.0
|
L
 -10.5%
H
42.0
54.2
|
L
 5.0%
H
40.0
54.2
|
L
 67.4%
H
23.1
54.2
|
L
 94.8%
H
17.3
54.2
|
L
 326.7%
H
9.1
54.2
|
L
H
6.5
54.2
|
Milestone Pharmaceuticals Inc |
|
121.1
|
2.3
|
L
 -5.8%
H
2.2
2.5
|
L
 22.0%
H
1.8
2.5
|
L
H
1.5
2.5
|
L
 28.3%
H
1.5
2.5
|
L
 56.6%
H
1.1
2.5
|
L
 -56.1%
H
1.1
9.9
|
L
 -82.1%
H
1.1
17.0
|
L
H
1.1
28.0
|
MoonLake Immunotherapeutic... |
|
2,516.1
|
39.8
|
L
 2.8%
H
38.7
41.0
|
L
 8.2%
H
36.5
41.0
|
L
 -8.0%
H
36.5
44.6
|
L
 -26.2%
H
36.5
56.9
|
L
 -15.9%
H
36.5
56.9
|
L
 299.6%
H
4.3
65.0
|
L
H
4.3
65.0
|
L
H
4.3
65.0
|
Mannkind Corp |
|
1,584.7
|
5.2
|
L
 -0.4%
H
5.1
5.3
|
L
 4.6%
H
4.9
5.3
|
L
 -3.7%
H
4.8
5.9
|
L
 -12.0%
H
4.8
7.1
|
L
 16.8%
H
4.0
7.6
|
L
 44.6%
H
2.6
7.6
|
L
 397.1%
H
0.9
7.6
|
L
 -80.8%
H
0.7
36.6
|
Mind Medicine Inc |
|
483.1
|
6.4
|
L
 -0.9%
H
6.2
6.5
|
L
 1.8%
H
6.0
6.8
|
L
 -35.2%
H
5.8
10.4
|
L
 -12.4%
H
5.8
10.4
|
L
 -30.1%
H
5.0
12.2
|
L
 -62.5%
H
2.1
20.0
|
L
 80.6%
H
2.1
86.6
|
L
H
0.0
154.8
|
Medicinova Inc |
|
73.6
|
1.5
|
L
 -2.6%
H
1.5
1.6
|
L
 2.7%
H
1.5
1.6
|
L
 -23.9%
H
1.5
2
|
L
 -29.6%
H
1.5
2.2
|
L
 15.4%
H
1.1
2.6
|
L
 -38.3%
H
1.1
3.2
|
L
 -63.9%
H
1.1
13.3
|
L
 -54.1%
H
1.1
14.5
|
TNF Pharmaceuticals Inc. |
|
1.1
|
0.4
|
L
H
0.4
0.4
|
L
 8.3%
H
0.3
0.4
|
L
 -31.6%
H
0.3
0.7
|
L
 -68.3%
H
0.3
1.6
|
L
 -86.5%
H
0.3
3.5
|
L
 -89.3%
H
0.1
6.2
|
L
 -89.7%
H
0.1
17.7
|
L
 -100.0%
H
0.1
2027.5
|
NewAmsterdam Pharma Compan... |
|
2,608.2
|
23.8
|
L
 1.8%
H
22.8
23.8
|
L
 1.6%
H
22.2
24
|
L
 19.3%
H
17.2
24.2
|
L
 -10.8%
H
17.2
26.9
|
L
 7.8%
H
15.2
27.3
|
L
 142.1%
H
5.6
32.9
|
L
H
5.6
32.9
|
L
H
5.6
32.9
|
Neurocrine Biosciences, Inc. |
|
10,922.5
|
109.6
|
L
 -1.8%
H
109.4
111.1
|
L
 -1.2%
H
105.2
112.7
|
L
 -4.8%
H
105.2
122.4
|
L
 -19.9%
H
105.2
154.6
|
L
 -21.2%
H
105.2
158.0
|
L
 16.9%
H
75.3
158.0
|
L
 37.6%
H
71.9
158.0
|
L
 157.6%
H
31.3
158.0
|
Minerva Neurosciences Inc |
|
11.2
|
1.6
|
L
 2.6%
H
1.6
1.7
|
L
 1.9%
H
1.5
1.7
|
L
 -18.8%
H
1.4
2.1
|
L
 -28.6%
H
1.4
2.7
|
L
 -42.7%
H
1.4
3.7
|
L
 -72.2%
H
1.3
15.3
|
L
 -96.5%
H
1.3
121.7
|
L
 -96.7%
H
1.3
126.7
|
Nektar Therapeutics |
|
188.0
|
0.9
|
L
 -3.3%
H
0.9
0.9
|
L
 7.3%
H
0.8
1.0
|
L
 -10.2%
H
0.8
1.1
|
L
 -13.7%
H
0.7
1.3
|
L
 2.3%
H
0.7
1.9
|
L
 -84.1%
H
0.4
6.4
|
L
 -94.5%
H
0.4
26.8
|
L
 -93.8%
H
0.4
111.4
|
NLS Pharmaceutics Ltd |
|
6.4
|
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 -7.7%
H
1.5
1.7
|
L
 -30.5%
H
1.5
2.4
|
L
 -17.8%
H
1.5
3.4
|
L
 -87.3%
H
0.1
18.4
|
L
 -96.9%
H
0.1
75.2
|
L
H
0.1
294
|
L
H
0.1
294
|
Nurix Therapeutics Inc |
|
1,038.1
|
13.7
|
L
 -1.8%
H
13.5
13.9
|
L
 0.7%
H
13.0
14.9
|
L
 -22.2%
H
13.0
18.1
|
L
 -34.4%
H
13.0
21.4
|
L
 4.6%
H
11.9
29.6
|
L
 -6.9%
H
4.2
29.6
|
L
H
4.2
52.4
|
L
H
4.2
52.4
|
NeuroSense Therapeutics Ltd |
|
26.0
|
1.1
|
L
 -5.1%
H
1.1
1.2
|
L
 3.7%
H
1.0
1.2
|
L
 -3.5%
H
1.0
1.2
|
L
 20.4%
H
1.0
1.3
|
L
 -18.8%
H
0.5
2.3
|
L
 -25.3%
H
0.4
8.2
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
NRX Pharmaceuticals Inc |
|
26.5
|
2.2
|
L
 5.4%
H
2.0
2.2
|
L
 4.4%
H
2.0
2.4
|
L
 -24.2%
H
1.8
3.0
|
L
 31.7%
H
1.4
6.0
|
L
 -52.5%
H
1.1
54
|
L
 -93.3%
H
1.1
54
|
L
 -97.9%
H
1.1
769.9
|
L
H
1.1
769.9
|
Nuvectis Pharma Inc |
|
215.4
|
9.2
|
L
 -3.0%
H
8.8
9.5
|
L
 20.9%
H
7.0
9.8
|
L
 18.1%
H
5.9
9.8
|
L
 80.2%
H
4.4
9.8
|
L
 -16.3%
H
4.4
11.9
|
L
 20.7%
H
4.4
20.9
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
Nextcure Inc |
|
17.6
|
0.6
|
L
 -1.6%
H
0.6
0.7
|
L
 -14.9%
H
0.6
0.8
|
L
 -17.1%
H
0.6
0.8
|
L
 -35.1%
H
0.6
1
|
L
 -56.6%
H
0.6
2.6
|
L
 -87.8%
H
0.6
5.4
|
L
 -98.4%
H
0.6
40.9
|
L
H
0.6
109
|
Ocugen Inc |
|
151.8
|
0.5
|
L
 -8.8%
H
0.5
0.6
|
L
 -7.1%
H
0.5
0.6
|
L
 -27.8%
H
0.5
0.8
|
L
 -37.4%
H
0.5
1
|
L
 -51.9%
H
0.5
2.1
|
L
 -84.2%
H
0.3
4.0
|
L
 79.3%
H
0.2
18.8
|
L
 -99.9%
H
0.2
659.4
|
Oculis Holding AG |
|
888
|
18.5
|
L
 -1.8%
H
18.4
18.9
|
L
 1.1%
H
17.5
19.3
|
L
 -14.3%
H
17.5
21.9
|
L
 6.0%
H
16.8
23.1
|
L
 62.7%
H
10.6
23.1
|
L
 90.3%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
Ocular Therapeutix Inc |
|
1,203.8
|
7.6
|
L
 -4.7%
H
7.6
8.3
|
L
 -1.1%
H
7.5
8.9
|
L
 4.0%
H
5.8
8.9
|
L
 -16.8%
H
5.8
9.2
|
L
 -20.0%
H
4.1
11.8
|
L
 39.4%
H
2
11.8
|
L
 51.4%
H
2
24.3
|
L
 -82.1%
H
2
44.2
|
Opus Genetics Inc. |
|
34.4
|
1.1
|
L
 16.0%
H
0.9
1.2
|
L
 17.2%
H
0.9
1.2
|
L
 -3.5%
H
0.9
1.2
|
L
 10.1%
H
0.9
1.5
|
L
 -42.6%
H
0.9
2.3
|
L
 -68.3%
H
0.9
6.6
|
L
 -82.4%
H
0.9
14.8
|
L
 -99.7%
H
0.9
390.2
|
Olema Pharmaceuticals Inc |
|
305.9
|
4.1
|
L
 -7.4%
H
4.1
4.4
|
L
 -6.8%
H
4.0
4.7
|
L
 -17.1%
H
4.0
5.3
|
L
 -34.6%
H
4.0
6.7
|
L
 -64.3%
H
4.0
16.6
|
L
 -9.5%
H
2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
Omeros Corporation |
|
507.1
|
8.8
|
L
 2.7%
H
8.4
8.9
|
L
 24.3%
H
7.0
8.9
|
L
 -4.7%
H
7.0
10.0
|
L
 11.0%
H
7.0
13.6
|
L
 139.7%
H
2.6
13.6
|
L
 37.1%
H
0.9
13.6
|
L
 -8.3%
H
0.9
25.5
|
L
 -63.0%
H
0.9
30.2
|
Oncternal Therapeutics Inc |
|
1.6
|
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.5
|
L
 -93.4%
H
0.5
9.9
|
L
 -66.2%
H
0.3
10.6
|
L
 -84.1%
H
0.3
10.6
|
L
 -99.0%
H
0.3
179.2
|
OptiNose Inc |
|
58.3
|
5.8
|
L
 -1.4%
H
5.6
6.0
|
L
 6.2%
H
5.3
6.3
|
L
 -3.3%
H
5.1
6.5
|
L
 -15.5%
H
0.4
7.3
|
L
 -79.4%
H
0.4
31.5
|
L
 -83.4%
H
0.4
64.5
|
L
 -90.9%
H
0.4
150
|
L
H
0.4
450
|
ORIC Pharmaceuticals Inc |
|
544.1
|
7.7
|
L
 -3.2%
H
7.6
7.9
|
L
 0.4%
H
7.2
8.1
|
L
 -8.4%
H
7.2
9.5
|
L
 -5.4%
H
7.2
14.7
|
L
 -49.3%
H
6.3
15.4
|
L
 15.5%
H
2.4
16.7
|
L
H
2.4
40.8
|
L
H
2.4
40.8
|
Oramed Pharmaceuticals, Inc |
|
97.2
|
2.4
|
L
 1.7%
H
2.4
2.5
|
L
 -4.0%
H
2.3
2.7
|
L
 0.4%
H
2.0
2.7
|
L
 2.6%
H
2.0
3.1
|
L
 -17.5%
H
2.0
3.1
|
L
 -75.7%
H
1.7
13.7
|
L
 -14.8%
H
1.7
31.5
|
L
 -37.9%
H
1.7
31.5
|
Outlook Therapeutics Inc |
|
47.1
|
1.5
|
L
 -4.6%
H
1.4
1.5
|
L
 4.3%
H
1.4
1.6
|
L
 -21.4%
H
1.3
1.9
|
L
 2.1%
H
1.3
2.6
|
L
 -82.2%
H
0.9
12.9
|
L
 -99.8%
H
0.9
848
|
L
 -99.3%
H
0.9
1704
|
L
H
0.9
17568
|
Ovid Therapeutics Inc |
|
32.7
|
0.5
|
L
 -2.1%
H
0.5
0.5
|
L
 -6.1%
H
0.4
0.6
|
L
 -28.1%
H
0.4
0.7
|
L
 -56.6%
H
0.4
1.1
|
L
 -83.1%
H
0.4
3.5
|
L
 -85.4%
H
0.4
4.1
|
L
 -80.7%
H
0.4
9.4
|
L
H
0.4
15.9
|
Phibro Animal Health Corp.... |
|
880.1
|
21.7
|
L
 -0.6%
H
21.4
21.8
|
L
 -6.4%
H
20.3
23.2
|
L
 -15.7%
H
20.3
26.6
|
L
 -2.7%
H
19.7
26.6
|
L
 76.1%
H
12.1
26.6
|
L
 9.6%
H
9.4
26.6
|
L
 10.1%
H
9.4
31
|
L
 -38.3%
H
9.4
54.6
|
Palisade Bio Inc |
|
2.4
|
0.8
|
L
 -5.9%
H
0.8
0.8
|
L
 -3.6%
H
0.8
1.1
|
L
 -23.1%
H
0.8
1.1
|
L
 -57.9%
H
0.8
2.6
|
L
 -85.2%
H
0.4
9.7
|
L
 -99.9%
H
0.4
1147.5
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
2878200
|
Panbela Therapeutics Inc. |
|
1.9
|
0.4
|
L
 8.1%
H
0.4
0.4
|
L
 11.1%
H
0.4
0.4
|
L
 17.7%
H
0.3
0.5
|
L
 17.7%
H
0.3
0.5
|
L
 -33.3%
H
0.3
0.7
|
L
 -100.0%
H
0.3
52560
|
L
 -100.0%
H
0.3
240000
|
L
 -100.0%
H
0.3
384000
|
Puma Biotechnology Inc |
|
165.2
|
3.3
|
L
 2.8%
H
3.1
3.3
|
L
 -2.6%
H
3.1
3.6
|
L
 16.4%
H
2.7
3.8
|
L
 14.0%
H
2.7
4.1
|
L
 -33.4%
H
2.2
6.1
|
L
 4.7%
H
1.6
7.7
|
L
 -47.0%
H
1.6
14.1
|
L
 -98.6%
H
1.6
252.9
|
Pacira BioSciences Inc |
|
1,084.3
|
23.4
|
L
 0.5%
H
22.6
23.7
|
L
 1.4%
H
21.8
23.7
|
L
 -7.9%
H
21.8
26.9
|
L
 18.2%
H
18.2
27.6
|
L
 -20.3%
H
11.2
31.7
|
L
 -68.1%
H
11.2
82.2
|
L
 -24.9%
H
11.2
82.2
|
L
 -75.6%
H
11.2
99.5
|
Processa Pharmaceuticals Inc |
|
2.2
|
0.5
|
L
 2.2%
H
0.4
0.5
|
L
 -4.2%
H
0.4
0.5
|
L
 -23.3%
H
0.4
0.6
|
L
 -54.5%
H
0.4
1.1
|
L
 -79%
H
0.4
3.3
|
L
 -85.9%
H
0.2
5.9
|
L
 -95.3%
H
0.2
14.2
|
L
 -99.4%
H
0.2
83.3
|
PDS Biotechnology Corporation |
|
62.4
|
1.4
|
L
 4.5%
H
1.3
1.4
|
L
 16.7%
H
1.2
1.4
|
L
 -10.3%
H
1.1
2.2
|
L
 -27.1%
H
1.1
2.2
|
L
 -71.4%
H
1.1
5
|
L
 -77.9%
H
1.1
13.7
|
L
 79.5%
H
0.6
17.9
|
L
H
0.6
517.4
|
Phathom Pharmaceuticals Inc |
|
389.3
|
5.6
|
L
 15.5%
H
5.0
5.9
|
L
 27.1%
H
4.1
5.9
|
L
 -3.1%
H
4.1
7.0
|
L
 -33.2%
H
4.1
8.6
|
L
 -34.2%
H
4.1
19.7
|
L
 -56.2%
H
4.1
19.7
|
L
 -81.3%
H
4.1
64.5
|
L
H
4.1
64.5
|
Pharvaris NV |
|
870.4
|
16.1
|
L
 -2.7%
H
16.1
16.7
|
L
 7.7%
H
14.5
18.0
|
L
 -7.1%
H
14.1
18.0
|
L
 -13.2%
H
14.1
19.9
|
L
 -31.3%
H
14.1
26.6
|
L
 -7.2%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
Praxis Precision Medicines... |
|
757.9
|
37.6
|
L
 -3.4%
H
36.4
39.5
|
L
 3.8%
H
35.3
39.7
|
L
 -58.6%
H
30.0
91.6
|
L
 -47.1%
H
30.0
91.8
|
L
 -31.8%
H
30.0
91.8
|
L
 -77.4%
H
11.9
200.0
|
L
H
11.9
914.3
|
L
H
11.9
914.3
|
PainReform Ltd |
|
2.5
|
2.8
|
L
 -3.4%
H
2.8
2.9
|
L
 -5.4%
H
2.7
3.0
|
L
 -0.4%
H
2.7
5.5
|
L
 8.5%
H
2.2
16.6
|
L
 -74.6%
H
0.2
16.6
|
L
 -95.7%
H
0.2
158.5
|
L
H
0.2
471
|
L
H
0.2
471
|
Procaps Group S.A |
|
85.7
|
0.8
|
L
H
0.8
0.8
|
L
 -22.5%
H
0.8
0.9
|
L
 -49.3%
H
0.8
1.3
|
L
 -78.1%
H
0.8
3.7
|
L
 -75.8%
H
0.5
3.7
|
L
 -91.0%
H
0.5
9.5
|
L
 -92.0%
H
0.5
12.0
|
L
H
0.5
12.0
|
ProQR Therapeutics N.V |
|
173.6
|
1.7
|
L
 -2.9%
H
1.6
1.7
|
L
 -8.8%
H
1.6
1.9
|
L
 -31.8%
H
1.6
2.7
|
L
 -40.7%
H
1.6
3.0
|
L
 -35.6%
H
1.6
4.6
|
L
 65%
H
0.5
4.6
|
L
 -70.3%
H
0.5
9.5
|
L
 -93.2%
H
0.5
25.4
|
Plus Therapeutics Inc |
|
3.3
|
0.6
|
L
 -5.1%
H
0.5
0.6
|
L
 -55.9%
H
0.5
1.9
|
L
 -54.8%
H
0.2
2.3
|
L
 -47.7%
H
0.2
2.3
|
L
 -67.6%
H
0.2
2.7
|
L
 -96.2%
H
0.2
18
|
L
 -96.6%
H
0.2
81.3
|
L
 -100.0%
H
0.2
163125
|
PTC Therapeutics Inc |
|
4,389.1
|
55.7
|
L
 -2.7%
H
55.1
57.2
|
L
 6.0%
H
50.7
58.4
|
L
 7.4%
H
44.3
58.4
|
L
 18.4%
H
41.7
58.4
|
L
 88.3%
H
24
58.4
|
L
 51.6%
H
17.5
59.8
|
L
 54.2%
H
17.5
70.8
|
L
 -28.2%
H
4.0
78.7
|
Protagenic Therapeutics Inc |
|
1.9
|
0.3
|
L
 -7.1%
H
0.3
0.3
|
L
 -7.1%
H
0.2
0.3
|
L
 -3.7%
H
0.2
0.5
|
L
 -53.6%
H
0.2
0.8
|
L
 -77.4%
H
0.2
1.9
|
L
 -92.3%
H
0.2
4.2
|
L
 -96.0%
H
0.2
28
|
L
 -99.8%
H
0.2
154.6
|
Petros Pharmaceuticals Inc |
|
1.8
|
0.1
|
L
 -12.5%
H
0.1
0.1
|
L
 -22.2%
H
0.1
0.1
|
L
 -75.9%
H
0.1
0.2
|
L
 -78.8%
H
0.1
0.7
|
L
 -95.4%
H
0.1
1.7
|
L
 -99.4%
H
0.1
28.8
|
L
H
0.1
59.6
|
L
H
0.1
59.6
|
Pulmatrix Inc |
|
27.8
|
7.6
|
L
 -9.2%
H
7.5
8.1
|
L
 12.4%
H
6.9
8.7
|
L
 -1.4%
H
6.4
10.4
|
L
 23.5%
H
5.7
10.4
|
L
 353.6%
H
1.6
10.4
|
L
 14.4%
H
1.6
10.4
|
L
 -61.5%
H
1.6
60.8
|
L
 -99.6%
H
1.6
2910
|
Polypid Ltd |
|
29.6
|
2.9
|
L
 -5.5%
H
2.8
3.1
|
L
 5.8%
H
2.8
3.2
|
L
 -1.7%
H
2.7
3.3
|
L
 16%
H
2.6
3.9
|
L
 -47.2%
H
2.4
5.5
|
L
 -98.3%
H
2.4
207
|
L
H
2.4
583.5
|
L
H
2.4
583.5
|
Pyxis Oncology Inc |
|
65.4
|
1.1
|
L
 -5.2%
H
1.1
1.2
|
L
 2.8%
H
1.0
1.2
|
L
 -16.7%
H
1.0
1.4
|
L
 -30.8%
H
1.0
1.8
|
L
 -78.5%
H
1.0
6.2
|
L
 -77.5%
H
1.0
6.9
|
L
H
1.0
19
|
L
H
1.0
19
|
Pharming Group N.V. - ADR |
|
667.3
|
8.9
|
L
 1.6%
H
8.8
9.0
|
L
 12.3%
H
7.7
9.2
|
L
 -2.8%
H
7.7
9.7
|
L
 1.6%
H
7.7
11.1
|
L
 -22.2%
H
6.7
11.8
|
L
 1.1%
H
6.1
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
Purple Biotech Ltd - ADR |
|
7.4
|
2.8
|
L
 -0.4%
H
2.7
2.8
|
L
 2.6%
H
2.6
2.9
|
L
 -10%
H
2.6
3.5
|
L
 -26.6%
H
2.6
5.0
|
L
 -80.8%
H
2.4
20.6
|
L
 -95.8%
H
2.4
85.6
|
L
 -94.3%
H
2.4
288
|
L
H
2.4
1390
|
Qilian International Holdi... |
|
995.6
|
10.2
|
L
H
10.2
10.3
|
L
 2.6%
H
9.5
10.3
|
L
 0.8%
H
8.6
11.3
|
L
 19.1%
H
7.7
14.8
|
L
 239.1%
H
2.6
14.8
|
L
 30.4%
H
1.8
14.8
|
L
H
1
110
|
L
H
1
110
|
Quoin Pharmaceuticals Ltd ... |
|
2.5
|
0.3
|
L
H
0.3
0.3
|
L
 3.5%
H
0.3
0.3
|
L
 -3.2%
H
0.3
0.5
|
L
 -53.9%
H
0.3
0.8
|
L
 -68.8%
H
0.3
1.6
|
L
 -99.9%
H
0.3
337.3
|
L
 -100.0%
H
0.3
5328
|
L
H
0.3
40500
|
RAPT Therapeutics Inc |
|
145.2
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 2.8%
H
1.0
1.3
|
L
 -8.3%
H
1.0
1.3
|
L
 31.0%
H
0.8
2.3
|
L
 -87.0%
H
0.8
9.7
|
L
 -95.1%
H
0.8
32.5
|
L
 -92.1%
H
0.8
43.3
|
L
H
0.8
51.2
|
Ultragenyx Pharmaceutical ... |
|
3,605.7
|
39.0
|
L
 -1.7%
H
38.7
39.5
|
L
 4.0%
H
37.3
40.5
|
L
 -8.3%
H
37.1
45
|
L
 -13.3%
H
37.1
46.5
|
L
 -17.7%
H
37.0
60.4
|
L
 -43.4%
H
31.5
85.5
|
L
 3.9%
H
31.5
179.7
|
L
 -37.3%
H
31.5
179.7
|
Regeneron Pharmaceuticals,... |
|
73,279.2
|
670.3
|
L
 -1.2%
H
667.0
678.3
|
L
 -10.0%
H
657
747.7
|
L
 -0.5%
H
657
748.3
|
L
 -9.2%
H
642
748.3
|
L
 -30.5%
H
642
1211.2
|
L
 -2.2%
H
538.0
1211.2
|
L
 36.3%
H
424.0
1211.2
|
L
 43.3%
H
271.4
1211.2
|
Regencell Bioscience Holdi... |
|
303.2
|
23.3
|
L
 26.0%
H
20.1
30
|
L
 466.9%
H
4.0
30
|
L
 521.3%
H
3.7
30
|
L
 374.5%
H
3.5
30
|
L
 404.3%
H
3.0
32.4
|
L
 -26.0%
H
3.0
48.3
|
L
H
3.0
59
|
L
H
3.0
59
|
Repligen Corp. |
|
8,105.6
|
144.4
|
L
 -5.5%
H
139.1
147.6
|
L
 5.4%
H
137.6
153.9
|
L
 -1.7%
H
135.7
169
|
L
 -8.9%
H
135.7
182.5
|
L
 -24.0%
H
113.5
200.2
|
L
 -20.2%
H
110.5
262.3
|
L
 48.0%
H
78.4
327.3
|
L
 360.5%
H
20.1
327.3
|
Regulus Therapeutics Inc |
|
91.1
|
1.4
|
L
 1.5%
H
1.3
1.5
|
L
 4.5%
H
1.3
1.6
|
L
 14.9%
H
1.2
1.6
|
L
 -14.2%
H
0.8
1.7
|
L
 -34.1%
H
0.8
3
|
L
 -52.7%
H
0.8
3.8
|
L
 -71.0%
H
0.8
23.2
|
L
 -99.9%
H
0.8
2443.2
|
Regenxbio Inc |
|
389.2
|
7.8
|
L
 11%
H
6.8
7.9
|
L
 29.3%
H
5.7
7.9
|
L
 6.4%
H
5.6
7.9
|
L
 -8.3%
H
5.6
8.8
|
L
 -65.0%
H
5.6
23.1
|
L
 -72.9%
H
5.6
35.7
|
L
 -71.1%
H
5.6
50.3
|
L
H
5.6
85.1
|
Rigel Pharmaceuticals |
|
368.7
|
20.6
|
L
 -1.9%
H
20.6
21.2
|
L
 5.7%
H
18.5
21.2
|
L
 -4.3%
H
18.4
23.5
|
L
 9.0%
H
14.6
24.5
|
L
 1417.7%
H
0.8
29.8
|
L
 533.1%
H
0.6
29.8
|
L
 1313.7%
H
0.6
29.8
|
L
 484.7%
H
0.6
29.8
|
Relmada Therapeutics Inc |
|
8.8
|
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 7.4%
H
0.3
0.3
|
L
 -12.1%
H
0.2
0.4
|
L
 -21.6%
H
0.2
0.5
|
L
 -94.7%
H
0.2
5.8
|
L
 -98.8%
H
0.2
38.7
|
L
 -98.9%
H
0.2
54
|
L
 -99.6%
H
0.2
70.8
|
RenovoRx Inc |
|
35.2
|
1.0
|
L
 -1%
H
1.0
1.0
|
L
 8.8%
H
0.9
1.1
|
L
 -4.8%
H
0.9
1.1
|
L
 -20.8%
H
0.9
1.7
|
L
 -25%
H
0.8
1.7
|
L
 -67.5%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
Roivant Sciences Ltd |
|
7,635.0
|
10.7
|
L
 -1.4%
H
10.6
10.9
|
L
 1.1%
H
10.4
11.0
|
L
 1.3%
H
10.0
11.0
|
L
 -10.5%
H
10.0
12.2
|
L
 5.5%
H
9.8
13.1
|
L
 105.0%
H
2.5
13.2
|
L
H
2.5
16.8
|
L
H
2.5
16.8
|
Royalty Pharma plc - Ordin... |
|
14,546.7
|
33.6
|
L
 1.7%
H
33
33.6
|
L
 2.5%
H
32
33.6
|
L
 3.7%
H
32
34.2
|
L
 33.6%
H
24.1
34.2
|
L
 11.6%
H
24.1
34.2
|
L
 -15.6%
H
24.1
44.8
|
L
H
24.1
56.5
|
L
H
24.1
56.5
|
Repare Therapeutics Inc |
|
48.9
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.3
|
L
 -9.5%
H
1.1
1.4
|
L
 -25.3%
H
1.1
1.5
|
L
 -78.3%
H
1.1
5.5
|
L
 -91.4%
H
1.1
18.7
|
L
H
1.1
46.4
|
L
H
1.1
46.4
|
Reviva Pharmaceuticals Hol... |
|
51.7
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 -4.3%
H
1.0
1.2
|
L
 -38.3%
H
1.0
1.9
|
L
 -14.0%
H
1.0
2.2
|
L
 -64.8%
H
0.6
4.3
|
L
 -38.3%
H
0.5
9.3
|
L
 -89.3%
H
0.5
15.1
|
L
H
0.5
15.1
|
Rezolute Inc |
|
198.0
|
3.3
|
L
 -6.6%
H
3.3
3.6
|
L
 -9.2%
H
3.3
3.8
|
L
 -29.1%
H
3.3
4.8
|
L
 -26.4%
H
3.3
5.7
|
L
 83.7%
H
1.7
6.2
|
L
 21.6%
H
0.7
6.2
|
L
 -26.5%
H
0.7
33.5
|
L
 -96.4%
H
0.7
112.5
|
Redhill Biopharma - ADR |
|
3.6
|
2.8
|
L
 -7.3%
H
2.6
2.9
|
L
 -7.6%
H
2.5
3.2
|
L
 -46.7%
H
2.5
5.8
|
L
 -60.2%
H
2.5
7.3
|
L
 -78.8%
H
2.5
20.3
|
L
 -99.9%
H
2.5
3270
|
L
 -99.9%
H
2.5
11520
|
L
 -100.0%
H
2.5
22220
|
Sage Therapeutics Inc |
|
485.7
|
7.9
|
L
 -1.5%
H
7.8
8.0
|
L
 8.7%
H
7.0
8.2
|
L
 10.6%
H
7.0
8.2
|
L
 47.9%
H
5.0
8.2
|
L
 -60.4%
H
4.6
20.3
|
L
 -76.7%
H
4.6
60.0
|
L
 -72.6%
H
4.6
98.4
|
L
 -83.2%
H
4.6
196.0
|
Sunshine Biopharma Inc |
|
5.5
|
2.0
|
L
 -1.5%
H
2.0
2.1
|
L
 -10.6%
H
1.9
2.4
|
L
 -19.1%
H
1.9
2.6
|
L
 -25.9%
H
1.9
3.6
|
L
 -66.2%
H
0.1
13.3
|
L
 -99.3%
H
0.1
987
|
L
 -97.5%
H
0.1
18890
|
L
 -100.0%
H
0.1
400000
|
Scilex Holding Company |
|
56.8
|
0.3
|
L
 3.3%
H
0.3
0.3
|
L
 -11.4%
H
0.3
0.4
|
L
 -11.4%
H
0.2
0.4
|
L
 -38%
H
0.2
0.5
|
L
 -77.4%
H
0.2
2.3
|
L
 -97.0%
H
0.2
16.9
|
L
H
0.2
16.9
|
L
H
0.2
16.9
|
scPharmaceuticals Inc |
|
152.1
|
3.0
|
L
 1.3%
H
2.9
3.1
|
L
 5.2%
H
2.9
3.2
|
L
 -17.4%
H
2.8
3.8
|
L
 -6.5%
H
2.8
3.9
|
L
 -47.9%
H
2.8
6.0
|
L
 -41.7%
H
2.8
12.8
|
L
 -50.7%
H
2.8
12.8
|
L
H
2.4
18.2
|
Scynexis Inc |
|
41.3
|
1.1
|
L
 -3.6%
H
1.0
1.1
|
L
 15.2%
H
0.8
1.2
|
L
 -5.4%
H
0.8
1.2
|
L
 -4.5%
H
0.8
1.5
|
L
 -26.9%
H
0.8
3.1
|
L
 -78.3%
H
0.8
5.2
|
L
 -83.7%
H
0.8
10.5
|
L
 -98.9%
H
0.8
103.4
|
Shuttle Pharmaceuticals Ho... |
|
2.0
|
0.4
|
L
 -8.9%
H
0.4
0.4
|
L
 -6.8%
H
0.3
0.5
|
L
 -41.4%
H
0.3
0.7
|
L
 -37.9%
H
0.3
1.0
|
L
 -88.9%
H
0.3
4.7
|
L
H
0.3
1010.1
|
L
H
0.3
1010.1
|
L
H
0.3
1010.1
|
SIGA Technologies Inc |
|
405.0
|
5.7
|
L
 0.7%
H
5.4
5.7
|
L
 -0.7%
H
5.3
6.2
|
L
 -7.7%
H
5.2
6.3
|
L
 -6.9%
H
5.2
6.6
|
L
 -22.7%
H
5.2
12.8
|
L
 -20.6%
H
4.2
27.0
|
L
 21.2%
H
4
27.0
|
L
 141.3%
H
0.2
27.0
|
SILO Pharma Inc |
|
6.0
|
1.3
|
L
 -3.6%
H
1.3
1.4
|
L
 8.1%
H
1.2
1.5
|
L
 -5.6%
H
1.2
1.5
|
L
 38.1%
H
0.8
3.4
|
L
 -27.2%
H
0.8
4.5
|
L
 -81.6%
H
0.8
496
|
L
 -93.3%
H
0.8
496
|
L
 -97.8%
H
0.8
496
|
Sol-Gel Technologies Ltd |
|
15.9
|
0.6
|
L
H
0.5
0.6
|
L
 -3.4%
H
0.5
0.7
|
L
 -6.6%
H
0.5
0.7
|
L
 16.3%
H
0.4
1.7
|
L
 -45.2%
H
0.3
1.7
|
L
 -92.4%
H
0.3
8.0
|
L
 -91.2%
H
0.3
16.7
|
L
H
0.3
21
|
Soleno Therapeutics Inc |
|
2,287.8
|
49.9
|
L
 0.5%
H
47.7
50.3
|
L
 14.2%
H
43
50.5
|
L
 1.5%
H
43
50.9
|
L
 4.7%
H
41.5
52.5
|
L
 14.8%
H
36.6
60.9
|
L
 975.2%
H
0.9
60.9
|
L
 95.6%
H
0.9
65.9
|
L
 -89.3%
H
0.9
618
|
Acelyrin Inc |
|
275.9
|
2.8
|
L
H
2.7
2.8
|
L
 5.8%
H
2.6
2.8
|
L
 29.1%
H
2.1
2.8
|
L
 -21.4%
H
1.8
4.0
|
L
 -64.9%
H
1.8
8.6
|
L
H
1.8
29.9
|
L
H
1.8
29.9
|
L
H
1.8
29.9
|
SELLAS Life Sciences Group... |
|
84.9
|
1.1
|
L
 -4.4%
H
1.1
1.1
|
L
 -7.7%
H
1.1
1.2
|
L
 -18.2%
H
1.1
1.4
|
L
 22.7%
H
0.8
1.8
|
L
 -1.8%
H
0.8
1.8
|
L
 -83.2%
H
0.5
7.4
|
L
 -40.7%
H
0.5
19.4
|
L
 -100.0%
H
0.5
74703
|
Soligenix Inc |
|
5.8
|
2.3
|
L
 -1.3%
H
2.3
2.4
|
L
 3.1%
H
2.2
2.4
|
L
 -2.5%
H
2.1
2.5
|
L
 -22.9%
H
2.0
3.7
|
L
 -76.5%
H
1.8
85.3
|
L
 -98.6%
H
1.8
240.0
|
L
 -99.4%
H
1.8
717.6
|
L
 -99.9%
H
1.8
7080.1
|
Sonoma Pharmaceuticals Inc. |
|
5.5
|
3.4
|
L
 -11.9%
H
3.3
3.8
|
L
 21.9%
H
2.8
4.5
|
L
 36.6%
H
1.9
4.5
|
L
 31.3%
H
1.9
4.5
|
L
 2328.6%
H
0.1
5.9
|
L
 11.1%
H
0.1
5.9
|
L
 -16.0%
H
0.1
19.6
|
L
 -90.4%
H
0.1
88.7
|
Synaptogenix Inc |
|
3.8
|
2.8
|
L
 1.1%
H
2.8
2.9
|
L
 0.7%
H
2.7
3.2
|
L
 -6.0%
H
2.6
3.3
|
L
 4.4%
H
2.5
4
|
L
 1315%
H
0.2
6.2
|
L
 -57.4%
H
0.1
8.8
|
L
H
0.1
14.5
|
L
H
0.1
14.5
|
SciSparc Ltd |
|
3.8
|
0.4
|
L
 -5.4%
H
0.3
0.4
|
L
 -12.5%
H
0.3
0.4
|
L
 -30%
H
0.3
0.5
|
L
 52.2%
H
0.2
1.8
|
L
 -85.3%
H
0.2
3.6
|
L
 -99.7%
H
0.2
181.7
|
L
H
0.2
221
|
L
H
0.2
221
|
ARS Pharmaceuticals Inc |
|
1,119.6
|
11.5
|
L
 0.7%
H
11.1
11.8
|
L
 6.4%
H
10.7
12.5
|
L
 -4.2%
H
10
12.5
|
L
 -1.0%
H
10
15.2
|
L
 25.8%
H
7.6
18.5
|
L
 189.4%
H
2.6
18.5
|
L
H
2.6
63.4
|
L
H
2.6
63.4
|
SeqLL Inc. |
|
282.3
|
5.6
|
L
 40.8%
H
5.1
6
|
L
H
5.1
6
|
L
H
5.1
6
|
L
H
5.1
6
|
L
H
5.1
6
|
L
 346.8%
H
0.2
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
Sarepta Therapeutics Inc |
|
7,401.6
|
76.3
|
L
 -24.7%
H
75.1
81.9
|
L
 -23.5%
H
75.1
103.3
|
L
 -29.3%
H
75.1
110
|
L
 -39.3%
H
75.1
129.8
|
L
 -38.0%
H
75.1
173.3
|
L
 -3.6%
H
55.3
173.3
|
L
 -12.1%
H
55.3
181.8
|
L
 461.3%
H
8
181.8
|
Sutro Biopharma Inc |
|
75.9
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 -31.9%
H
0.8
1.4
|
L
 -48.6%
H
0.8
1.9
|
L
 -56.0%
H
0.8
2.2
|
L
 -77.6%
H
0.8
6.1
|
L
 -89.9%
H
0.8
9.8
|
L
 -87.2%
H
0.8
28.3
|
L
H
0.8
28.3
|
Supernus Pharmaceuticals Inc |
|
1,790.5
|
32.1
|
L
 -0.3%
H
31.6
32.1
|
L
 -2.3%
H
30.8
32.9
|
L
 -18.0%
H
30.4
40.0
|
L
 -11.4%
H
30.4
40.3
|
L
 -2.7%
H
25.5
40.3
|
L
 2.6%
H
22
42.1
|
L
 119.6%
H
13.1
42.1
|
L
 189.5%
H
9.5
61.3
|
Sinovac Biotech, Ltd. |
|
464.9
|
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
L
H
6.5
6.5
|
Savara Inc |
|
482.2
|
2.8
|
L
H
2.7
2.9
|
L
 5.6%
H
2.5
2.9
|
L
 -0.4%
H
2.3
2.9
|
L
 -12.7%
H
2.3
3.4
|
L
 -40.3%
H
2.3
5.3
|
L
 134.2%
H
1.1
5.7
|
L
 18.6%
H
1
5.7
|
L
 -91.9%
H
0.7
49.6
|
SpringWorks Therapeutics Inc |
|
3,694.3
|
49.3
|
L
 -1.1%
H
48.7
50.3
|
L
 1.8%
H
47.4
52.4
|
L
 -14.2%
H
46.6
62
|
L
 30.7%
H
32.0
62
|
L
 -2.0%
H
28.2
62
|
L
 -20.2%
H
13.6
65.9
|
L
 125.5%
H
13.6
96.5
|
L
H
13.6
96.5
|
China SXT Pharmaceuticals Inc |
|
1.4
|
2.7
|
L
 3.8%
H
2.6
2.8
|
L
 -1.8%
H
2.6
3.2
|
L
 615.8%
H
0.3
5.7
|
L
 700%
H
0.3
5.7
|
L
 56.3%
H
0.3
5.7
|
L
 -45.1%
H
0.3
57
|
L
 -95.3%
H
0.3
128
|
L
H
0.3
2335
|
Sanofi - ADR |
|
148,199.6
|
59.1
|
L
 0.3%
H
58.7
59.2
|
L
 -0.4%
H
57.3
59.9
|
L
 8.5%
H
53.5
60.1
|
L
 20.8%
H
46.9
60.1
|
L
 22.4%
H
45.2
60.1
|
L
 12.4%
H
36.9
60.1
|
L
 35.5%
H
36.9
60.1
|
L
 20.7%
H
36.8
60.1
|
Talaris Therapeutics Inc |
|
-
|
17.4
|
L
 -36.4%
H
17.3
18.4
|
L
H
17.3
18.4
|
L
H
17.3
18.4
|
L
H
17.3
18.4
|
L
H
17.3
18.4
|
L
 119.1%
H
0
31.3
|
L
H
0
31.3
|
L
H
0
31.3
|
Protara Therapeutics Inc |
|
156.3
|
4.3
|
L
 -3.9%
H
4.2
4.4
|
L
 13.3%
H
3.8
4.5
|
L
 2.2%
H
3.2
4.5
|
L
 -23.2%
H
3.2
6.2
|
L
 15.5%
H
1.6
10.5
|
L
 -14.8%
H
1.0
10.5
|
L
 -85.3%
H
1.0
67.1
|
L
 -99.1%
H
1.0
800
|
Tarsus Pharmaceuticals Inc |
|
1,912.3
|
46.4
|
L
 -2.2%
H
45.4
47.1
|
L
 4.1%
H
43.9
49.9
|
L
 -7.6%
H
40.4
51.3
|
L
 -10.8%
H
40.4
57.3
|
L
 47.0%
H
20.1
57.3
|
L
 157.9%
H
10.8
57.3
|
L
H
10.8
63.7
|
L
H
10.8
63.7
|
Theravance Biopharma Inc |
|
463.5
|
9.4
|
L
 0.2%
H
9.3
9.5
|
L
 -1.0%
H
9.1
9.5
|
L
 -2.5%
H
8.8
10.2
|
L
 -3.4%
H
8.4
10.9
|
L
 8.5%
H
7.4
10.9
|
L
 -10.8%
H
7.4
12.0
|
L
 -48.7%
H
6.1
31.4
|
L
 -49.7%
H
6.1
43.4
|
Tenax Therapeutics Inc |
|
25.1
|
6.3
|
L
 1.8%
H
6.2
6.3
|
L
 5.3%
H
5.8
6.6
|
L
 -11.9%
H
5.6
7.4
|
L
 12.6%
H
5.4
7.9
|
L
 69.1%
H
2.8
7.9
|
L
 -99.3%
H
2.8
1360
|
L
 -99.2%
H
2.8
5888
|
L
 -100.0%
H
2.8
127360
|
TG Therapeutics Inc |
|
6,287.5
|
40.0
|
L
 -2.5%
H
38.8
40.7
|
L
 2.0%
H
36.8
41.9
|
L
 30.4%
H
28.2
41.9
|
L
 19.2%
H
27.2
41.9
|
L
 163.0%
H
12.9
41.9
|
L
 313.5%
H
3.5
41.9
|
L
 422.6%
H
3.5
56.7
|
L
 128.4%
H
3.3
56.7
|
Third Harmonic Bio Inc |
|
158.6
|
3.5
|
L
 1.2%
H
3.4
3.6
|
L
 2.0%
H
3.4
3.6
|
L
 -2.2%
H
3.3
3.7
|
L
 -68.9%
H
3.2
11.8
|
L
 -62.4%
H
3.2
16.9
|
L
H
3.2
24.6
|
L
H
3.2
24.6
|
L
H
3.2
24.6
|
Theratechnologies Inc. |
|
71.3
|
1.6
|
L
 -3.7%
H
1.6
1.6
|
L
 3.3%
H
1.5
1.6
|
L
 -11.4%
H
1.5
2.1
|
L
 -4.3%
H
1.4
2.2
|
L
 23.0%
H
1.1
2.2
|
L
 -85.0%
H
0.9
11.1
|
L
 -77.6%
H
0.9
17.8
|
L
 -35.4%
H
0.9
45
|
Alpha Teknova Inc |
|
296.0
|
5.5
|
L
 -2.0%
H
5.4
5.6
|
L
 0.4%
H
5.1
6.5
|
L
 -33.1%
H
5.1
8.7
|
L
 -35.7%
H
5.1
10.4
|
L
 94.4%
H
1.2
10.4
|
L
 -61.2%
H
1.2
17.6
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
Tiziana Life Sciences Ltd |
|
154.7
|
1.5
|
L
 -3.9%
H
1.5
1.6
|
L
 -3.9%
H
1.3
1.6
|
L
 88.6%
H
0.8
1.9
|
L
 50.5%
H
0.6
1.9
|
L
 198%
H
0.4
1.9
|
L
 38.0%
H
0.4
1.9
|
L
 63.7%
H
0.4
12.2
|
L
H
0.4
12.2
|
Tonix Pharmaceuticals Hold... |
|
116.3
|
20.8
|
L
 27.8%
H
15.5
21.4
|
L
 54.5%
H
12.4
21.4
|
L
 74.1%
H
6.8
21.4
|
L
 -37.7%
H
0.2
72
|
L
 -98.0%
H
0.2
1193.3
|
L
 -100.0%
H
0.2
169600
|
L
 -100.0%
H
0.2
1574400
|
L
 -100.0%
H
0.2
6860800000
|
Tenaya Therapeutics Inc |
|
108.9
|
0.7
|
L
 -8.2%
H
0.7
0.7
|
L
 31.4%
H
0.5
0.7
|
L
 -44.2%
H
0.4
1.2
|
L
 -52.5%
H
0.4
1.9
|
L
 -86.6%
H
0.4
5.4
|
L
 -93.8%
H
0.4
14.4
|
L
H
0.4
32
|
L
H
0.4
32
|
Tempest Therapeutics Inc |
|
37.1
|
0.9
|
L
 -1.2%
H
0.8
0.9
|
L
 7.6%
H
0.8
0.9
|
L
 -8.6%
H
0.7
1.0
|
L
 7.6%
H
0.7
1.1
|
L
 -76.7%
H
0.7
6
|
L
 -67.3%
H
0.2
9
|
L
 -99.0%
H
0.2
105.3
|
L
 -100.0%
H
0.2
12530.3
|
Trevena Inc |
|
1.1
|
1.2
|
L
 -10.8%
H
1.2
1.3
|
L
 -17.9%
H
1.2
1.6
|
L
 -31.5%
H
1.2
1.8
|
L
 -25.3%
H
1.2
2.0
|
L
 -91.0%
H
0.2
14.2
|
L
 -99.6%
H
0.2
381.9
|
L
 -99.7%
H
0.2
2300
|
L
 -100.0%
H
0.2
8481.3
|
2seventy bio Inc |
|
259.4
|
5.0
|
L
 0.2%
H
5.0
5.0
|
L
 77.1%
H
4.9
5.0
|
L
 95.3%
H
2.4
5.0
|
L
 53.6%
H
2.3
5.0
|
L
 23.7%
H
2.3
6.0
|
L
 -66.7%
H
1.5
19.3
|
L
H
1.5
64
|
L
H
1.5
64
|
Titan Pharmaceuticals, Inc... |
|
3.5
|
3.8
|
L
 1.6%
H
3.5
3.8
|
L
 15.2%
H
3.2
3.8
|
L
 -6.2%
H
3.2
4.5
|
L
 9.9%
H
3.0
4.5
|
L
 -59.3%
H
3.0
14.8
|
L
 278%
H
0.3
14.8
|
L
 -43.8%
H
0.3
14.8
|
L
 -99.4%
H
0.3
1800
|
Travere Therapeutics Inc |
|
1,803.2
|
20.3
|
L
 -2.6%
H
19.8
20.9
|
L
 13.7%
H
17.7
21.0
|
L
 -11.3%
H
17.2
23.7
|
L
 17.9%
H
16.6
25.3
|
L
 171.3%
H
5.1
25.3
|
L
 -17.6%
H
5.1
30.4
|
L
 91.3%
H
5.1
33.1
|
L
 37.7%
H
5.1
37.0
|
TherapeuticsMD Inc |
|
8.6
|
0.8
|
L
 -2.6%
H
0.7
0.8
|
L
 -6.3%
H
0.7
0.8
|
L
 -27.2%
H
0.7
1.7
|
L
 -34.2%
H
0.7
2.4
|
L
 -68.8%
H
0.7
2.6
|
L
 -96.1%
H
0.7
23
|
L
 -98.8%
H
0.7
137.5
|
L
 -99.7%
H
0.7
563
|
Universe Pharmaceuticals INC |
|
1.4
|
0.1
|
L
 -10%
H
0.1
0.1
|
L
 -30.8%
H
0.1
0.1
|
L
 -43.8%
H
0.1
0.4
|
L
 -87.0%
H
0.1
0.7
|
L
 -93.9%
H
0.1
4.9
|
L
 -98.7%
H
0.1
12.5
|
L
H
0.1
71.9
|
L
H
0.1
71.9
|
United Therapeutics Corp |
|
14,254.7
|
317.4
|
L
 -1.7%
H
316.7
324.6
|
L
 -0.2%
H
299.5
324.6
|
L
 -14.4%
H
299.5
383.5
|
L
 -16.4%
H
299.5
383.5
|
L
 34.6%
H
221.5
417.8
|
L
 72.0%
H
173.2
417.8
|
L
 294.0%
H
75.6
417.8
|
L
 79.0%
H
74.3
417.8
|
Vericel Corp |
|
2,356.1
|
47.2
|
L
 -1.0%
H
46.8
48
|
L
 -3.5%
H
45.2
49.1
|
L
 -17.4%
H
45.2
58.8
|
L
 -18.9%
H
45.2
63
|
L
 6.5%
H
39.1
63
|
L
 36.6%
H
17.3
63
|
L
 403.7%
H
6.8
68.9
|
L
 1191.8%
H
1.7
68.9
|
Veru Inc |
|
70.3
|
0.5
|
L
 -4%
H
0.5
0.5
|
L
 -4%
H
0.5
0.5
|
L
 -11.1%
H
0.5
0.6
|
L
 -32.4%
H
0.5
1.4
|
L
 -17.2%
H
0.5
1.9
|
L
 -90.4%
H
0.4
24.6
|
L
 -82.7%
H
0.4
24.6
|
L
 -83.7%
H
0.4
24.6
|
Vincerx Pharma Inc |
|
1.6
|
0.7
|
L
 -12.1%
H
0.7
1.2
|
L
 -12.1%
H
0.7
1.2
|
L
 -43.9%
H
0.7
1.4
|
L
 284.2%
H
0.1
2
|
L
 -86.9%
H
0.1
7.6
|
L
 -83.6%
H
0.1
9.4
|
L
H
0.1
26.8
|
L
H
0.1
26.8
|
Dogwood Therapeutics Inc. |
|
7.6
|
5.7
|
L
 -6.7%
H
5.6
6.2
|
L
 -32.7%
H
5.6
14.7
|
L
 -7.3%
H
3.9
14.7
|
L
 142.7%
H
1.9
29.3
|
L
 1675%
H
0.1
29.3
|
L
 2.7%
H
0.1
29.3
|
L
H
0.1
29.3
|
L
H
0.1
29.3
|
Viking Therapeutics Inc |
|
3,295.6
|
29.4
|
L
 -1.6%
H
28.4
29.7
|
L
 5.0%
H
24.4
31.5
|
L
 -3.7%
H
24.4
36.4
|
L
 -37.1%
H
24.4
45
|
L
 -53.1%
H
24.4
89.1
|
L
 768.6%
H
2.0
99.4
|
L
 720.1%
H
2.0
99.4
|
L
H
0.9
99.4
|
Vanda Pharmaceuticals Inc |
|
288.7
|
5.0
|
L
 -2.6%
H
4.9
5.0
|
L
 5.1%
H
4.7
5.2
|
L
 12.0%
H
4.3
5.2
|
L
 4.7%
H
4.2
5.2
|
L
 29.9%
H
3.7
6.8
|
L
 -58.4%
H
3.3
12.3
|
L
 -38.1%
H
3.3
21.9
|
L
 -49.4%
H
3.3
33.4
|
Verrica Pharmaceuticals Inc |
|
60.6
|
0.7
|
L
 1.5%
H
0.6
0.7
|
L
 3.1%
H
0.5
0.7
|
L
 -10.8%
H
0.5
0.8
|
L
 -5.7%
H
0.5
0.8
|
L
 -86.3%
H
0.5
11.4
|
L
 -92.1%
H
0.5
11.4
|
L
 -92.5%
H
0.5
18.4
|
L
H
0.5
23.3
|
Viridian Therapeutics Inc |
|
1,236.9
|
15.2
|
L
 -5.4%
H
15.1
15.8
|
L
 -2.6%
H
15.0
17
|
L
 -7.4%
H
14.1
17
|
L
 -26.3%
H
14.1
21.1
|
L
 -11.2%
H
11.4
27.2
|
L
 -24.1%
H
9.5
39
|
L
 154.3%
H
4.7
39
|
L
 -97.2%
H
4.7
661.5
|
Virpax Pharmaceuticals Inc |
|
3.5
|
0.1
|
L
 -23.5%
H
0.1
0.1
|
L
 -31.6%
H
0.1
0.2
|
L
 -60.6%
H
0.1
0.3
|
L
 -61.8%
H
0.1
0.5
|
L
 -96.9%
H
0.1
4.8
|
L
 -94.0%
H
0.1
5.5
|
L
H
0.1
36
|
L
H
0.1
36
|
Vertex Pharmaceuticals, Inc. |
|
132,431.7
|
515.7
|
L
 0.4%
H
508.5
516.3
|
L
 3.1%
H
480.3
519.7
|
L
 12.4%
H
452.0
519.7
|
L
 9.9%
H
378
519.7
|
L
 26.5%
H
378
519.9
|
L
 106.3%
H
233.0
519.9
|
L
 145.1%
H
176.4
519.9
|
L
 299.3%
H
71.5
519.9
|
Viatris Inc |
|
11,387.8
|
9.5
|
L
 3.1%
H
9.3
9.6
|
L
 0.4%
H
9.0
9.6
|
L
 -11.7%
H
8.8
11.5
|
L
 -23.4%
H
8.8
12.7
|
L
 -20.1%
H
8.8
13.6
|
L
 -10.3%
H
8.4
13.6
|
L
 -38.7%
H
8.4
19.2
|
L
 -84.8%
H
8.4
76.7
|
vTv Therapeutics Inc - Ord... |
|
52.8
|
20.2
|
L
 -11.1%
H
20.2
23.6
|
L
 34.7%
H
14.5
27.0
|
L
 -6.9%
H
14.5
27.0
|
L
 30.6%
H
13.2
27.0
|
L
 12.3%
H
12.1
31.0
|
L
 3009.2%
H
0.4
31.0
|
L
 1054.9%
H
0.4
31.0
|
L
H
0.4
31.0
|
VYNE Therapeutics Inc |
|
27.4
|
1.8
|
L
 -3.7%
H
1.7
1.9
|
L
 -9.1%
H
1.7
2.1
|
L
 -27.1%
H
1.7
2.9
|
L
 -29.4%
H
1.7
4.3
|
L
 -10.5%
H
1.6
4.3
|
L
 -83.6%
H
1.6
14.2
|
L
 -99.0%
H
1.6
259.2
|
L
H
1.6
2869.9
|
Vaccitech plc - ADR |
|
39.3
|
1.0
|
L
 -71.0%
H
1.0
1.1
|
L
H
1.0
1.1
|
L
H
1.0
1.1
|
L
H
1.0
1.1
|
L
H
1.0
1.1
|
L
 -82.1%
H
1.0
7.5
|
L
H
1.0
18.0
|
L
H
1.0
18.0
|
Verona Pharma Plc - ADR |
|
5,371.5
|
63.2
|
L
 -5.0%
H
63.0
66.6
|
L
 3.0%
H
59.5
68.6
|
L
 -1.6%
H
59.5
70.4
|
L
 51.7%
H
39.7
70.4
|
L
 303.9%
H
11.4
70.4
|
L
 1182.2%
H
3.4
70.4
|
L
 2072.2%
H
2.0
70.4
|
L
H
2.0
70.4
|
Walgreens Boots Alliance Inc |
|
9,685.0
|
11.2
|
L
 -0.5%
H
11.2
11.3
|
L
 -0.7%
H
11.2
11.3
|
L
 15.5%
H
9.6
11.9
|
L
 12.3%
H
9.1
13.3
|
L
 -46.2%
H
8.1
22.1
|
L
 -76.4%
H
8.1
48.6
|
L
 -77.4%
H
8.1
57.1
|
L
 -87.0%
H
8.1
97.3
|
Windtree Therapeutics Inc |
|
1.3
|
1.8
|
L
 -6.3%
H
1.8
1.9
|
L
 -1.1%
H
1.8
2.2
|
L
 -74.3%
H
1.8
6
|
L
 -90.5%
H
1.8
20
|
L
 -99.4%
H
1.8
737.5
|
L
 -100.0%
H
1.8
64350
|
L
 -100.0%
H
1.8
504900
|
L
 -100.0%
H
1.8
1000036.8
|
Xenetic Biosciences Inc |
|
5.7
|
3.7
|
L
H
3.5
3.7
|
L
 0.8%
H
3.3
3.8
|
L
 -8.5%
H
3.3
4.2
|
L
 -9.6%
H
3.3
4.3
|
L
 -15.6%
H
2.8
5.2
|
L
 -63.7%
H
2.4
12.5
|
L
 -35.6%
H
2.4
58.5
|
L
 -99.6%
H
2.4
4514
|
Xenon Pharmaceuticals Inc |
|
2,695.1
|
35.2
|
L
 -1.1%
H
34.5
35.5
|
L
 2.8%
H
33.8
36.2
|
L
 -9.5%
H
33.3
40
|
L
 -14.2%
H
33.3
41.7
|
L
 -19.9%
H
33.3
46
|
L
 14.2%
H
24.9
51.0
|
L
 252.5%
H
7
51.0
|
L
 98.3%
H
2.1
51.0
|
Xilio Therapeutics Inc |
|
41.4
|
0.8
|
L
 -1.2%
H
0.8
0.8
|
L
 -4.8%
H
0.7
0.9
|
L
 -29.8%
H
0.7
1.2
|
L
 -16.7%
H
0.6
1.7
|
L
 17.7%
H
0.6
1.9
|
L
 -89.4%
H
0.5
9.6
|
L
H
0.5
28.0
|
L
H
0.5
28.0
|
XOMA Corp |
|
244.5
|
20.8
|
L
 0.1%
H
20.3
21.3
|
L
 -1.9%
H
19.9
21.6
|
L
 -22.5%
H
19.9
26.8
|
L
 -23.5%
H
19.9
29.0
|
L
 -21.2%
H
19.9
35
|
L
 -24.9%
H
13.5
35
|
L
 22.8%
H
13.5
46.3
|
L
 -73.5%
H
4.0
98.6
|
XORTX Therapeutics Inc |
|
3.1
|
1.0
|
L
 -2.1%
H
1.0
1.0
|
L
 -2.1%
H
0.9
1.1
|
L
 5.6%
H
0.8
1.3
|
L
 -22.1%
H
0.8
1.8
|
L
 -81.6%
H
0.8
5.4
|
L
 -18.1%
H
0.3
7
|
L
 -28.0%
H
0.3
8.2
|
L
H
0.3
8.2
|
Y-Mabs Therapeutics Inc |
|
203.0
|
4.5
|
L
 -5.7%
H
4.5
4.7
|
L
 -5.7%
H
4.5
5.0
|
L
 -28.0%
H
4.3
6.6
|
L
 -52.9%
H
4.3
9.7
|
L
 -69.5%
H
4.3
17.8
|
L
 -58.7%
H
2.7
20.9
|
L
 -75.1%
H
2.7
55.2
|
L
H
2.7
55.2
|
Zevra Therapeutics Inc |
|
438.3
|
8.1
|
L
 -3.0%
H
8.0
8.4
|
L
 1.3%
H
7.3
8.5
|
L
 0.4%
H
7.2
8.5
|
L
 -4.5%
H
7.2
9.0
|
L
 35%
H
4.2
9.8
|
L
 43.6%
H
3.9
9.8
|
L
 148.5%
H
1.9
22.1
|
L
H
1.9
418.4
|
ZyVersa Therapeutics Inc |
|
1.9
|
0.8
|
L
 -3.8%
H
0.7
0.8
|
L
 -19.2%
H
0.7
1.0
|
L
 -38.7%
H
0.7
1.3
|
L
 -23.2%
H
0.7
2.0
|
L
 -2.6%
H
0.6
6.7
|
L
H
0.1
25
|
L
H
0.1
25
|
L
H
0.1
25
|
Zymeworks BC Inc |
|
864.1
|
12.4
|
L
 -1.3%
H
12.1
13.0
|
L
 11.9%
H
11.0
13.2
|
L
 -17.3%
H
11.0
15.3
|
L
 -7.1%
H
11.0
17
|
L
 14.9%
H
8.0
17.7
|
L
 74.2%
H
4.1
17.7
|
L
 -55.0%
H
4.1
59.0
|
L
H
4.1
59.0
|
Sagimet Biosciences Inc - ... |
|
125.6
|
3.9
|
L
 2.9%
H
3.7
3.9
|
L
 9.9%
H
3.3
3.9
|
L
 -8.5%
H
3.2
4.5
|
L
 -36.0%
H
3.2
7.4
|
L
 -3.7%
H
2.4
7.4
|
L
 -49.0%
H
2.1
20.7
|
L
 -49.0%
H
2.1
20.7
|
L
 -49.0%
H
2.1
20.7
|
Ocean Biomedical Inc. |
|
8.4
|
0.1
|
L
H
0.1
0.1
|
L
 -25%
H
0.1
0.1
|
L
 -53.9%
H
0.1
0.2
|
L
 -90.5%
H
0.1
0.8
|
L
 -98.5%
H
0.1
5.0
|
L
 -97%
H
0.1
7.8
|
L
 -97%
H
0.1
7.8
|
L
 -97%
H
0.1
7.8
|
CervoMed Inc |
|
76.1
|
9.2
|
L
 1.9%
H
8.8
10.2
|
L
 315.3%
H
1.9
10.2
|
L
 295.7%
H
1.9
10.2
|
L
 375.3%
H
1.9
10.2
|
L
 -48.8%
H
1.8
26.4
|
L
 -52.5%
H
1.8
29.7
|
L
 -56.9%
H
1.8
138.8
|
L
 -100.0%
H
1.8
34312.5
|
Dianthus Therapeutics Inc |
|
657.9
|
20.5
|
L
 -6.8%
H
20.4
22.6
|
L
 -15.9%
H
20
24.3
|
L
 -16.4%
H
18.1
25.3
|
L
 -14.0%
H
18.1
28.6
|
L
 -27.0%
H
18.1
33.8
|
L
 2594.7%
H
6.6
33.8
|
L
 2594.7%
H
6.6
33.8
|
L
 2594.7%
H
6.6
33.8
|
Neumora Therapeutics Inc. |
|
184.7
|
1.1
|
L
 -4.2%
H
1.1
1.2
|
L
 -14.9%
H
1.1
1.5
|
L
 -34.5%
H
1.1
1.8
|
L
 -89.3%
H
1.1
11.6
|
L
 -92.5%
H
1.1
17.2
|
L
H
1.1
21
|
L
H
1.1
21
|
L
H
1.1
21
|
Agape ATP Corp |
|
4.1
|
1.0
|
L
 1.0%
H
1.0
1.0
|
L
 -3.7%
H
1
1.1
|
L
 8.4%
H
0.9
2.3
|
L
 -12.0%
H
0.9
2.9
|
L
 171.1%
H
0.1
3.5
|
L
 -33.1%
H
0.1
3.5
|
L
 -33.1%
H
0.1
3.5
|
L
 -33.1%
H
0.1
3.5
|
Tourmaline Bio Inc |
|
450.8
|
17.6
|
L
 -3.9%
H
17.3
18.4
|
L
 19.8%
H
14.4
18.9
|
L
 26.9%
H
11.9
18.9
|
L
 -19.7%
H
11.9
22.1
|
L
 -59.4%
H
11.9
45.6
|
L
 550%
H
2.5
48.3
|
L
 550%
H
2.5
48.3
|
L
 550%
H
2.5
48.3
|
Barinthus Biotherapeutics ... |
|
41.0
|
1.0
|
L
 -1.9%
H
1.0
1.1
|
L
 6.3%
H
1.0
1.1
|
L
 -6.4%
H
0.9
1.2
|
L
 10.9%
H
0.9
1.3
|
L
 -58.9%
H
0.8
4.2
|
L
 -72.0%
H
0.8
5.1
|
L
 -72.0%
H
0.8
5.1
|
L
 -72.0%
H
0.8
5.1
|
Onconetix Inc |
|
1.7
|
0.1
|
L
 -7.7%
H
0.1
0.1
|
L
 -33.3%
H
0.1
0.2
|
L
 -77.8%
H
0.1
0.5
|
L
 -74.5%
H
0.1
2.1
|
L
 -98.1%
H
0.1
21.4
|
L
 -100.0%
H
0.1
2540
|
L
 -93.4%
H
0.1
3636
|
L
 -93.4%
H
0.1
3636
|
Talphera Inc. |
|
10.0
|
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 11.3%
H
0.5
0.6
|
L
 -11.9%
H
0.5
0.7
|
L
 -6.4%
H
0.5
0.8
|
L
H
0.5
1.2
|
L
H
0.5
1.2
|
L
H
0.5
1.2
|
L
H
0.5
1.2
|
ArriVent BioPharma Inc. |
|
673.5
|
19.8
|
L
 -3.7%
H
19.7
20.4
|
L
 -8.9%
H
19.7
22.7
|
L
 -25.6%
H
19.7
28.1
|
L
 -26.5%
H
19.7
29.7
|
L
 1.6%
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
Skye Bioscience Inc |
|
69.5
|
2.3
|
L
 -9.5%
H
2.3
2.5
|
L
 -9.8%
H
2.3
2.9
|
L
 -27.5%
H
2.3
3.4
|
L
 -29.5%
H
2.3
4.3
|
L
H
2.3
7.2
|
L
H
2.3
7.2
|
L
H
2.3
7.2
|
L
H
2.3
7.2
|
Actuate Therapeutics Inc. |
|
144.3
|
7.4
|
L
 -0.1%
H
7.3
7.5
|
L
 1.5%
H
6.9
7.6
|
L
 -4.8%
H
6.0
8.0
|
L
 -3.5%
H
6.0
11.7
|
L
H
5.5
11.7
|
L
H
5.5
11.7
|
L
H
5.5
11.7
|
L
H
5.5
11.7
|
Bicara Therapeutics Inc. |
|
688.9
|
12.7
|
L
 -6.2%
H
12.4
13.5
|
L
 -17.6%
H
12.0
15.8
|
L
 -6.1%
H
11.8
16.6
|
L
 -30.3%
H
11.1
19.8
|
L
H
11.1
28.1
|
L
H
11.1
28.1
|
L
H
11.1
28.1
|
L
H
11.1
28.1
|
Gelteq Ltd. |
|
12.1
|
1.3
|
L
 4.9%
H
1.0
1.3
|
L
 -5.2%
H
1.0
1.7
|
L
 -39.1%
H
1.0
2.3
|
L
 -60.5%
H
1.0
3.3
|
L
H
1.0
5.5
|
L
H
1.0
5.5
|
L
H
1.0
5.5
|
L
H
1.0
5.5
|
Septerna Inc. |
|
275.3
|
6.2
|
L
 -2.2%
H
6.2
6.7
|
L
 5.6%
H
5.8
6.9
|
L
 -52.2%
H
4.2
7.1
|
L
 -72.2%
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
Alpha Cognition Inc |
|
93.7
|
5.9
|
L
 2.8%
H
5.6
6.8
|
L
 7.0%
H
5.2
6.8
|
L
 -3.0%
H
4.9
6.9
|
L
 10.6%
H
4.8
7
|
L
H
4.8
7
|
L
H
4.8
7
|
L
H
4.8
7
|
L
H
4.8
7
|
Atlantic International Corp. |
|
-
|
5.6
|
L
 -5.9%
H
5.1
6
|
L
H
5.0
6.1
|
L
H
5.0
6.1
|
L
H
5.0
6.1
|
L
H
5.0
6.1
|
L
H
5.0
6.1
|
L
H
5.0
6.1
|
L
H
5.0
6.1
|
BeiGene Ltd - ADR |
|
28,131.0
|
261.7
|
L
 -1.3%
H
258.2
264.2
|
L
 7.9%
H
242.6
265.9
|
L
 13.4%
H
233.7
287.9
|
L
 41.7%
H
172.7
287.9
|
L
 41.7%
H
172.7
287.9
|
L
 41.7%
H
172.7
287.9
|
L
 41.7%
H
172.7
287.9
|
L
 41.7%
H
172.7
287.9
|
Jupiter Neurosciences Inc |
|
-
|
0.6
|
L
 -3.1%
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.6
|
Ascentage Pharma Group Int... |
|
1,696.1
|
19.5
|
L
 -1.0%
H
19.2
19.5
|
L
 4.7%
H
18.4
19.9
|
L
 6.8%
H
18.3
21.4
|
L
 12.1%
H
17
21.4
|
L
 12.1%
H
17
21.4
|
L
 12.1%
H
17
21.4
|
L
 12.1%
H
17
21.4
|
L
 12.1%
H
17
21.4
|
Metsera Inc. |
|
3,154.5
|
30.0
|
L
 5.5%
H
28.2
31.2
|
L
 19.7%
H
23.2
31.2
|
L
 -2.1%
H
23.2
32.8
|
L
H
23.2
32.8
|
L
H
23.2
32.8
|
L
H
23.2
32.8
|
L
H
23.2
32.8
|
L
H
23.2
32.8
|
Maze Therapeutics Inc. |
|
521.4
|
11.9
|
L
 3.7%
H
10.9
13.0
|
L
 1.1%
H
9.9
13
|
L
 -0.8%
H
9.9
13.2
|
L
H
9.9
17
|
L
H
9.9
17
|
L
H
9.9
17
|
L
H
9.9
17
|
L
H
9.9
17
|
Aardvark Therapeutics Inc. |
|
197.8
|
9.3
|
L
 -0.1%
H
8.7
10.1
|
L
 -9.8%
H
8.7
11.8
|
L
 -30.5%
H
8.7
19.6
|
L
H
8.7
19.6
|
L
H
8.7
19.6
|
L
H
8.7
19.6
|
L
H
8.7
19.6
|
L
H
8.7
19.6
|